Additional Defined Terms. The following terms shall have the meanings set forth on the pages of this Agreement indicated below: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)
Appears in 1 contract
Additional Defined Terms. The following In addition to the terms shall have the meanings set forth on the pages defined in Section 1 of this Appendix A, the following capitalized terms are defined in the body of the Agreement where indicated below: 280G Approval 6.3(cAccounting Referee 14.1(e) 280G Payments 6.3(cAcquired Assets 2.2 Acquired Interests 2.3(a) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAcquired Leases 2.3(a) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aAllocated Value 3.5 Asset 3.5 Assignment 13.3(a) Audited Balance Sheet 3.9(bBackground Materials 9.9(a) Audited Balance Sheet Date 3.9(bBase Purchase Price 3.1(a)(i) Audited Financial Statements 3.9(bBOEPD 3.2(b)(iv) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Change-In-Interest 5.2(a) Claim Notice 16.3(a) Closing 2.4 13.1(b) Closing Date 2.4 Closing Working Capital Estimate 2.17(a13.1(b) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eConfidential Information 10.13(b) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) Consent Decree Excluded ▇▇▇▇▇ Law 3.12(b10.21 Consent Decree ▇▇▇▇▇ 2.4(a) Stockholder Defect Adjustment 5.6(c) Defect Notice Deadline 5.5(a) Defensible Title 5.1 Deposit 3.3 Deposit Escrow Account 3.3 Deposit Escrow Agreement 3.3 Disclosed Environmental Matters 8.5 DTPA 17.4 Due Diligence Review 4.1(a) Environmental Assessment 6.1(b) Environmental Defect 6.2 Environmental Defect Value 6.3 Environmental Disputed Matters 6.8 Environmental Matters 6.9 Escrow Agent 3.3 Exchange Transaction 15.7(a) Exchanging Party 15.7(a) Excluded Assets 2.5 Execution Date Preamble Final Determination Date 14.1(i) Final First Closing Purchase Price 14.1(a) Final Purchase Price 14.1(b) Final Second Closing Purchase Price 14.1(b) Final Settlement Disputes 14.1(e) First Closing 13.1(a) First Closing Amount 3.4(b)(i) First Closing Assets 2.3 First Closing Assets Contracts 2.3(h) First Closing Assets Data 2.3(j) First Closing Assets Records 2.3(m) First Closing Assignment 13.2(a) First Closing Base Purchase Price 3.1(a)(ii) First Closing Date 13.1(a) First Closing Final Settlement Statement 14.1(a) First Closing Payment 3.4(b)(i)(A) First Closing Properties 2.3(c) First Closing Purchase Price 3.1(a)(iii) First Closing Settlement Date 14.1(a) First Closing Transition Services Agreement 13.2(l) First Closing ▇▇▇▇▇ 2.3(c) First Preliminary Settlement Statement 3.4(a)(i) Indemnified Party 16.3(a) Indemnifying Party 16.3(a) Information Request 10.13(c) Interest Addition 5.8(a) Interest Addition Amount 5.6(c) Interim Operation Approval 3.8 Stockholder Meeting 5.8(bThreshold 10.1(a) Straddle Intermediary 15.7(c) Joint Use Agreement 13.2(k)) Lands 2.3(b) Leased Lands 2.3(a) Material First Closing Assets Contracts 2.3(h) Material Second Closing Assets Contracts 2.4(f) NBLX Contracts 10.22 Negotiation Period 1.1 Subsidiary Securities 3.2(b14.1(d) Survival Net Aggregate Defect Value 5.6(c) Non-Consent Decree ▇▇▇▇▇ 2.4(a) Non-Exchanging Party 15.7(a) NORM 6.2 Notice of Environmental Defects 6.4(b) Notice of Title Defects 5.5(a) Objection 10.13(c) Objection Date 10.3(a14.1(c) Third Objection Report 14.1(c) Oil and Gas Property Taxes 15.1(a) Open Environmental Defect 6.6(a) Open Title Defect 5.7(a) Other Property Taxes 15.1(b) Party Preamble Parties Preamble Permitted Lien 5.2 Phase II Request 6.1(b)(ii) Production Values 3.2(b)(iv) Purchase Price 3.1(a)(iv) Purchaser Preamble Purchaser Defect Termination Notice 6.7(a) Purchaser’s Title Defect Value 5.6(b) S-X Financials 10.20 Second Closing 13.1(b) Second Closing Amount 3.4(b)(ii) Second Closing Assets 2.4 Second Closing Assets Contracts 2.4(f) Second Closing Assets Data 2.4(h) Second Closing Assets Records 2.4(k) Second Closing Assignment 13.3(a) Second Closing Base Purchase Price 3.1(a)(v) Second Closing Date 13.1(b) Second Closing Final Settlement Statement 14.1(b) Second Closing Payment 3.4(b)(ii) Second Closing Properties 2.4(a) Second Closing Purchase Price 3.1(a)(vi) Second Closing Settlement Date 14.1(b) Second Closing Transition Services Agreement 13.3(c) Second Closing ▇▇▇▇▇ 2.4(a) Second Preliminary Settlement Statement 3.4(a)(ii) Seller Preamble Seller’s Warranties 17.16(b) Settled Asset Taxes 15.2 Settled Oil and Gas Property Taxes 15.1(a) Settled Other Property Taxes 15.1(b) Settled Property Taxes 15.1(b) Settled Severance Taxes 15.2 Subject Consent Decree ▇▇▇▇▇ 10.21 Surviving Environmental Defect 6.5(b) Surviving Title Defect 5.6(b) Tax Controversy 15.8(d) Termination Dispute Notice 6.8(b) Termination Response Notice 6.8(b) Third-Party Claim 10.4(b16.3(b) Working Capital Deficit 2.17(fTitle Defect 5.3 Title Defect Value 5.4 Title Disputed Matters 5.9 Title/Environmental Termination Threshold 6.7(a) Working Capital Objection Period 2.17(eTitle LLC 15.7(d) Working Capital Objection Statement 2.17(eUnagreed Termination Environmental Matters 6.7(b) Working Capital Surplus 2.17(f)Unagreed Termination Title Matters 6.7(b) Wellbore Notice 10.21 Neither these Schedules nor any disclosure made in or by virtue of them constitutes or implies any representation, warranty, or covenant by Seller not expressly set out in the Agreement, and neither these Schedules nor any such disclosure has the effect of, or may be construed as, adding to, broadening, deleting from or revising the scope of any of the representations, warranties, or covenants of Seller in the Agreement. Any item or matter disclosed or listed on any particular Schedule is deemed to be disclosed or listed on any other Schedules to the extent it is reasonably apparent that such item relates or is applicable to, or is properly disclosed under, such other Schedule or the section of the Agreement to which such other Schedule corresponds, notwithstanding the fact that the Schedules are arranged to correspond to the sections of the Agreement, that a particular section of the Agreement makes reference to a particular Schedule, or that a particular representation, warranty or covenant in the Agreement may not make reference to a Schedule. Matters reflected in these Schedules are not necessarily limited to matters required by the Agreement to be reflected in these Schedules. The fact that any item of information is contained herein is not an admission of liability under any applicable law, and does not mean that such information is required to be disclosed in or by the Agreement, or that such information is material, but rather is intended only to qualify the representations, warranties and covenants in the Agreement and to set forth other information required by the Agreement. Neither the specification of any dollar amount in any representation, warranty or covenant contained in the Agreement nor the inclusion of any specific item in these Schedules is intended to imply that such amount, or a higher or lower amount, or the item so included, or any other item, is or is not material, and no party shall use the setting forth of any such amount or the inclusion of any such item in any dispute or controversy between or among the parties to the Agreement as to whether any obligation, item or matter not described herein or included in these Schedules is or is not material for purposes of the Agreement. The information set forth on the Schedules shall not be used as a basis for interpreting the terms “material”, “materially”, “materiality”, “Material Adverse Effect”, or any similar qualification in the Agreement. Neither the specification of any item or matter in any representation, warranty or covenant contained in the Agreement nor the inclusion of any specific item in these Schedules is intended to imply that such item or matter, or another item or matter, is or is not in the ordinary course of business, and no party shall use the setting forth or the inclusion of any such item or matter in any dispute or controversy between or among the parties to the Agreement as to whether any obligation, item or matter described or not described herein or included or not included in these Schedules is or is not in the ordinary course of business for purposes of the Agreement. Headings have been inserted in these Schedules for reference only and do not amend the descriptions of the disclosed items set forth in the Agreement. Where a reference is made to a section or exhibit, such reference shall be to a section of or exhibit to the Agreement unless otherwise indicated. Whenever the words “include,” “includes,” or “including” are used in these Schedules, they shall be deemed to be followed by the words “without limitation,” whether or not they are in fact followed by those words or words of like import. The following Schedules constitute Seller’s Disclosure Schedules:
8.1 Material Required Consents 8.2 Preferential Rights
Appears in 1 contract
Additional Defined Terms. The following capitalized terms shall have the respective meanings set forth on in the pages respective Sections of this Agreement indicated set forth opposite each such respective term below: . 280G Stockholder Approval 6.3(c) 6.13 280G Payments 6.3(cWaiver 7.2(c) 401(k) Plan 6.13 Action of Divestiture 6.8(a) Actual Cash 2.10(c) Actual Company Debt 2.10(c) Actual Excess Fees 2.10(c) Actual Working Capital 2.10(c) Acquisition Proposal 5.11 5.3(a) Acquisition Sub Preamble Agreed Claims 10.4(gTransaction 9.3(a)(i) Additional Shares 2.11(a)(i) Affected Stockholders 6.25(a) Agent Indemnification Expenses 8.7(d)(vii) Agent Interpleader Expenses 8.7(d)(vi) Agreement Preamble Agreement Applicable Expiration Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a8.1(a) Audited Balance Sheet 3.9(bBylaws 3.1(a) Audited Balance Sheet Date 3.9(b3.7 Cancellation Fees 6.9(d) Audited Financial Statements 3.9(bCancellation Notices 6.9(d) California Stockholder Approval 3.8 Certificate of Incorporation 3.1(a) Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 2.3(a) Change of Control Fees 6.9(d) Charter Documents 3.1(a) Claim Certificate 8.5(a) Closing 2.4 2.2 Closing Date 2.4 2.2 Closing Working Capital Estimate 2.17(aStatement Memorandum 2.10(c)(i) Company Preamble Company Authorizations 3.18 Company Board Approval 3.5 Company Certificate 2.10(e) Recommendation 3.4 Company Disclosure Schedule 3.0 Article III Company Disclosure Schedules 3.0 Company Option 2.13(aExpenses 9.3(b)(i) Company Preferred Stock 2.10(bIndemnified Parties 6.23(b) Company Representative 5.11 Company Software 3.18(lIntellectual Property Contracts 3.14(e)(i) Company Third Party Consents 6.3(bPrivacy Policy 3.14(m)(i) Company Warrant 2.14(aReleased Party 6.25(b) Company Warrant Documents 2.12(aReleasing Parties 6.25(b) Confidentiality Company Source Code 3.14(l) Company Stockholder Meeting 6.3(a) Company User Data 3.14(m)(i) Company Voting Proposal 3.4 Conflict 3.5 Consent Fees 6.9(a) Continuing Employee Options 6.11(c) Continuing Employee Restricted Stock Units 6.11(d) Copyrights 1.1(ggg) Critical Person Retention Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(aRecitals Current Balance Sheet 3.7 Deferred Merger Consideration 2.11(a)(i) DGCL Preamble Disclosure Statement 5.8(a2.1(a) D&O Policy 6.23(c) Director and Officer Resignation and Release Letter 6.10(b) Dissenting Share Payments 2.8(c) Dissenting Shares 2.15 Dissenting Stockholders 2.15 2.8(a) DOJ 6.2(a6.8(b) Domain Names 1.1(hhh) Earned Employee Restricted Stock Units 6.11(e) EBITDA Shares 2.11(a)(ii) EBITDA Target 2.11(a)(iv) EBITDA Target Floor 2.11(a)(iv) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f2.3(a) Escrow Agent 2.16 Escrow Agreement 2.16 Preamble Escrow Fund 2.16 8.7(a) Escrow Period 8.7(b)
(a) Estimated Closing Statement 2.10(a) Estimated Company Debt 2.10(a) Estimated Excess Fees 2.10(a) Estimated Working Capital Surplus 2.17(b2.10(a) FDA Requirements 3.19(aExcess Amount 2.9(b)(iv) Excess Fees 6.14 Exchange 6.25(a) Exchange Act 4.9(a) Expiration Date 8.1(a) FCPA 3.24 Final Adjusted Cash Consideration 2.10(b) Final Working Capital 2.17(eSurviving Entity 2.1(b) Firm 11.9 Financials 3.7 First Step Merger Recitals FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a6.8(b) Indemnified Parties 10.1(a8.2(a) Indemnified Party 8.2(a) Indemnifying Party 8.2(a) Interim Balance Sheet 3.9(b) Financials 3.7 Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(bSurviving Corporation 2.1(a) In-the-Money Company Option 2.13(aLicenses 3.14(e)(i) In-the-Money Company Warrant 2.14(aIssue Defect 6.25(a) Joint Instruction 8.7(c)(ii) Lease Agreements 3.13(b) Leased Real Property 3.14(a3.13(a) Letter Amendment Premable Letter of Transmittal 2.12(aLiabilities 3.9 Loss 8.2(a) License Agreement 3.16(a)(xiLosses 8.2(a) License Agreements 3.16(a)(xiMaterial Contract 3.16(a) Majority Effective Time Holders 9.1(cMaterial Contracts 3.16(a) Measurement Date 1.1 Maximum Aggregate Premium 6.23(c) Merger Recitals Merger Subs Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Merger Sub One Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Sub Two Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiModification Fees 6.9(b) ▇▇▇▇▇’▇ Law 3.12(b8.7(c)(ii) Stockholder Approval 3.8 Non-U.S. Benefit Plan 3.22(e) Notice of Dispute 2.10(d) Objection Notice 8.5(b) Open Source Material 3.14(k) Option Consideration 2.9(b)(vi) Optionholder’s Portion of the Merger Consideration 2.9(b)(vi) Out-Licenses 3.14(e)(i) Parent Preamble Parent Board Recommendation 4.2 Parent Disclosure Schedule Article IV Parent Expenses 9.3(a)(iv) Parent Plans 6.11(b) Parent Principal Stockholders Recitals Parent Stockholder Meeting 5.8(b6.2(a) Straddle Parent Stockholder Voting Agreement Recitals Parent Voting Proposal 4.2 Patents 1.1(ggg) Performance Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f2.11(a)(vi)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c10 Acquired Company Leased Real Property 3.8(b) 280G Payments 6.3(cAcquired Company Real Property 3.8(a) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Calculation 2.7(a) Adjustment Notice 2.7(a) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Statement 2.8(a) Alternative Transaction 5.14 Antitrust Filings 6.2(aLaws 5.3(b) Audited Assumed Benefit Plans 10.3 Assumed Liabilities 2.3 Balance Sheet 3.9(b3.5(a) Audited Books and Records 2.1(b) Business Information 5.6(b) Casualty Loss 5.11(b) China Formation Requirements 5.19 Claim Notice 8.3(a) Closing 2.9 Closing Balance Sheet 2.7(a) Closing Date 3.9(b2.9 Closing Net Cash Statement 2.7(a) Audited Closing Net Working Capital Statement 2.7(a) Closing Receivables 5.15 Commitment Letter 4.7 Confidentiality Agreement 5.6(a) Covenant IP 5.3(a) Credit Support Obligations 5.16 Deductible 8.5(a) Dispute Notice 2.7(b) Economic Sanctions 3.16(c) Employee Matters Agreement 2.1(d)
(a) Estimated Closing Net Cash 2.6
(a) Estimated Closing Net Working Capital 2.6(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Final Closing Net Cash 2.7(f) Final Closing Net Working Capital 2.7(f) Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a3.5(a) Fundamental Representations 10.2(a)(iiand Warranties 8.4(a) German Sale and Transfer Agreement 2.1(e) Governmental Antitrust Authority 5.3(b) 11 Guarantee 11.18(a) HSR Act 6.2(a5.3(b) Included Contracts 2.1(b) Indemnified D&Os 6.4(aParty 8.3(a) Indemnified Parties 10.1(aIndemnifying Party 8.3(a) Independent Accounting Firm 2.7(e) Insurance Policies 3.18 Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a3.5(a) Leased Real Property 3.14(a2.1(b) Letter Amendment Premable Letter of Transmittal 2.12(aLender 4.7 Local Transfer Agreements 2.1(c) License Agreement 3.16(a)(xiMaterial Contracts 3.10(a) License Agreements 3.16(a)(xiObligations 11.18(a) Majority Effective Time Holders 9.1(cOFAC 3.16(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(cOwned Real Property 2.1(b) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Phase I Closing 2.9 Phase I Closing Balance Sheet 2.17(c2.7(a) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Phase I Closing Net Working Capital Statement 2.17(c2.7(a) Paying Agent 2.11(aPhase I Closing Date 2.9 Phase I Outside Date 7.1(c) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Phase II Closing Period 6.1 Preliminary 2.9 Phase II Closing Balance Sheet 2.17(a2.7(a) Preliminary Phase II Closing Statement 2.17(aDate 2.9 Phase II Letter of Credit 2.10(b) Prior Merger Phase II Outside Date 7.2(c) Purchase Price 2.5 Purchase Price Reduction 2.13 Purchased Assets 2.1(b) Purchased Intellectual Property 2.1(b) Purchaser Preamble Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 8.1 Purchaser Supply Agreement Preamble Related Agreements 3.5(a2.10(a) Restrictive Covenant Agreement 2.10(a) Resolution Period 2.7(e) Revised Deductible 8.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fPreamble Seller Disclosure Schedule Article 3 Seller Indemnified Parties 8.2 Seller Signage 5.17 Seller Supply Agreement 2.10(a)
Appears in 1 contract
Additional Defined Terms. The following capitalized terms shall have the respective meanings set forth on in the pages respective Sections of this Agreement indicated set forth opposite each such respective terms below: 280G Approval 6.3(c401(k) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gPlan 6.9(b) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aRestraint 6.6(e) Audited Balance Sheet 3.9(bBusiness Partners 3.17(a)(viii) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 2.2 Certificates 2.8(c) Change of Recommendation Notice 6.3(d)(ii) Closing 2.4 2.2 Closing Date 2.4 Closing Working Capital Estimate 2.17(a2.2 Code 2.8(d) Company Preamble Company Board Approval 3.5 Balance Sheet 3.4(b) Company Certificate 2.10(eCharter Documents 3.1(b) Company Disclosure Schedule 3.0 Letter Article III Company Disclosure Schedules 3.0 Company Option 2.13(aFinancials 3.4(b) Company Preferred Stock 2.10(bMaterial Contract 3.17(a) Company Representative 5.11 Company Software 3.18(lPurchase Plans 3.2(c) Company Third Party Consents 6.3(bSEC Reports 3.4(a) Company Warrant 2.14(aStockholder Approval 3.3(a) Company Warrant Documents 2.12(aStockholders’ Meeting 6.2(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b6.4(a) Delivered Tax Returns 3.22(aContinuation Notice 6.3(e) DGCL Preamble Disclosure Statement 5.8(aContinuing Employees 6.9(e) Cutoff Time 3.2(a) Delaware Law RECITALS Dissenting Shares 2.7(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aStockholder 2.7(a) Effective Time 2.4 2.2 Employee Pension Termination Release 6.9(d)(iii) End Date 8.1(b) Engagement Letter 3.14(a) Fairness Opinion 3.20 GAAP 3.4(b) Governmental Authorizations 3.10 Indemnified Parties 6.10(a) Key Employee Non-Competition Agreements RECITALS Key Employee Offer Letters RECITALS Key Employee Severance Benefit Plan 3.15(h6.9(d)(iii) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(aKey Employees RECITALS Lease Documents 3.7(b) Leased Real Property 3.14(a3.7(a) Merger 2.1 Merger Consideration 2.6(a) Merger Sub Preamble Necessary Consents 3.3(c) Offer Letter Amendment Premable Letter of Transmittal 2.12(a6.9(d) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(bConsideration 2.6(b)(i) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(cPlans 6.9(e) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a2.8(a) Payment Fund 2.11(a2.8(b) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(aOffer Letter 6.9(d)(i) Preliminary Closing Statement 2.17(aRepresentatives 6.3(a) Prior Merger RSU Consideration 2.6(b)(ii) Section 262 2.7(a) Severance Benefit Plan 6.9(d)(iii) Significant Customer 3.22(a) Significant Supplier 3.22(b)
(a) Surviving Corporation 2.1 Tax Incentive 3.6(l) Terminated Employee 6.9(d)(iii) Triggering Event 8.1 Voting Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)RECITALS
Appears in 1 contract
Sources: Agreement and Plan of Merger (Nuance Communications, Inc.)
Additional Defined Terms. The following In addition to the terms defined in Section 1.1, additional defined terms used herein shall have the respective meanings set forth on assigned thereto in the pages Sections indicated in the table below. Defined Term Section 2008 Indenture Definition of this Agreement indicated below: 280G Approval 6.3(cLegacy Notes 2015 Indenture Definition of Legacy Notes Ad Hoc Guaranteed Group Backstop Parties Recitals Ad Hoc Guaranteed Group Backstop Premium Section 3.1(a) 280G Payments 6.3(cAd Hoc Guaranteed Group Holdback Notes Recitals Ad Hoc Guaranteed Group Holdback Shares Recitals Ad Hoc Legacy Group Backstop Parties Recitals Ad Hoc Legacy Group Backstop Premium Section 3.1(b) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Ad Hoc Legacy Group Holdback Notes Recitals Ad Hoc Legacy Group Holdback Shares Recitals Agreement Preamble Alternative Transaction Agreement Section 9.1(c)(ii) Alternative Transaction Proposal Section 6.8(a) Applicable Consent Section 4.7 Backstop Commitment Section 2.2 Backstop Escrow Account Section 2.4(a) Backstop Escrow Funding Date Section 2.4(b) Backstop Parties Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aBackstop Party Preamble Backstop Premiums Section 3.1(b) Audited Balance Sheet 3.9(bBankruptcy Code Preamble Bankruptcy Court Preamble BNY Mellon Definition of Legacy Notes Chapter 11 Cases Preamble Defined Term Section Closing Section 2.5(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(aSection 2.5(b) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eFleet Report Section 4.30(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aCover Transaction Period Section 2.3(d) Company Preferred Stock 2.10(bCustomary Securities Lending Arrangement Definition of Transfer Debtor Preamble Debtors Preamble Employee Representatives Section 4.14(a) Company Representative 5.11 Company Software 3.18(lEnvironmental Laws Section 4.19(a) Company Third Expense Reimbursement Section 3.3 Filing Party Consents 6.3(bSection 6.5(b) Company Warrant 2.14(aFinancial Reports Section 6.7(a) Company Warrant Documents 2.12(aFinancial Statements Section 4.9(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Foreign Benefit Plan 3.15(hSection 4.21(i) Employee Plan 3.15(hFunding Notice Section 2.4(a) Employee Welfare Benefit Plan 3.15(hGAAP Section 4.9(a) Environmental Approvals 3.21(eGuaranteed Backstop Party Replacement Section 2.3(a)(i) Environmental Reports 3.21(fGuaranteed Backstop Party Replacement Period Section 2.3(a)(i) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Guaranteed Notes Allocation Recitals
Appears in 1 contract
Additional Defined Terms. The following capitalized terms shall have the respective meanings set forth on in the pages respective Sections of this Agreement indicated set forth opposite each such respective term below: 280G Approval 6.3(cWaiver Recitals 401(k) 280G Payments 6.3(cPlan 7.13 Accountant 2.10(e)(ii) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAffiliates Legend 2.16(b) Agent Indemnification Expenses 9.7(d)(vii) Agent Interpleader Expenses 9.7(d)(vi) Agreement Preamble Agreement Alternate Transaction 6.4(a) Applicable Expiration Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a9.1(a) Audited Balance Sheet 3.9(bAppraiser 2.10(e)(ii) Audited Balance Sheet Date 3.9(b3.7 California Permit 7.12 Certificate of Incorporation 3.1(a) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 2.3 Charter Documents 3.1(a) Claim Certificate 9.5(a) Closing 2.4 2.2 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) 2.2 Company Preamble Company Board Approval Authorizations 3.21 Company Stock Certificates 2.9(b)(iii) Conflict 3.5 Company Certificate 2.10(eConsents 3.6 Current Balance Sheet 3.7 Customer Information 3.14(f) Company Deferred Merger Consideration 2.10(a)(ii)(2) Deferred Merger Consideration Notice 2.10(e)(i) Delaware Law 2.1 Director and Officer Resignation Letter 7.8(b) Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aArticle III Dispute Notice 2.10(e)(i) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(aDissenting Share Payments 2.8(c) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a2.8(a) Domain Names 1.1(bbb) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f2.3 Escrow Expenses 9.7(e) Escrow Agent 2.16 Fund 9.7(a) Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(bPeriod 9.7(b) FDA Requirements 3.19(aExcess Third Party Expenses 7.14 Exchange Documents 2.9(b)(iii) Final Working Capital 2.17(eExpiration Date 9.1(a) Firm 11.9 FTC 6.2(aFCPA 3.29 Financials 3.7 FIRPTA Compliance Certificate 7.17 First Milestone Amount 2.10(a)(i)(1) Fundamental Representations 10.2(a)(iiForm S-3 Registration Statement 7.11(c) HSR Act 6.2(aGovernmental Entity 3.6 Health Care Laws 3.18 Indemnified Parties 9.2(a) Indemnified D&Os 6.4(aParty 9.2(a) Indemnified Parties 10.1(aInformation Statement 7.1(a) Intellectual Property Contracts 1(a)(iii) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(aFinancials 3.7 Key Employee Offer Letters Recitals Lease Agreements 3.14(b) Leased Real Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a2.9(b)(i) License Agreement 3.16(a)(xiLoss 9.2(a) License Losses 9.2(a) Material Contract 3.17(a) Material Contracts 3.17(a) Merger Recitals Milestone Payment Date 2.10(a)(i) Non-Competition Agreements 3.16(a)(xiRecitals Objection Notice 9.5(b) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(bOffer Letter 7.9(a) Parent Preamble Parent Closing 10-K 4.6 Parent Balance Sheet 2.17(c5.6(b) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cFinancials 5.6(b) Parent Working Capital Statement 2.17(cPreferred Stock 5.5(a) Paying Agent 2.11(aParent SEC Reports 5.6(a) Paying Agent Agreement 2.11(aParent Stock Plans 5.5(a) Payment Fund 2.11(aPatents 1.1(bbb) Pre-Closing Permit Application 7.12 Principal Stockholder Preamble Principal Stockholders Preamble Required Stockholder Approval Recitals Returns 3.12(b)(i) Right of Setoff 2.10(g) RoHS Directive 1.1(jj) Second Milestone Amount 2.10(a)(ii)(1) Second Milestone Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiIncremental Sales 2.10(a)(ii)(1) Specified Representations 10.2(a)(iii9.1(a) ▇▇▇▇▇ Law 3.12(bSpreadsheet 7.15 Statement of Expenses 7.14 Stockholder Certificate 7.11(a) Stockholder Approval 3.8 Written Consent Recitals Stockholder Meeting 5.8(bWritten Consents Recitals Superior Transaction 6.4(d) Straddle Period 1.1 Subsidiary Securities 3.2(bSurviving Corporation 2.1 Tax 3.12(a) Survival Date 10.3(aTaxes 3.12(a) Terminated Agreements 7.7(b) Third Party Claim 10.4(b9.6(a) Working Capital Deficit 2.17(fThird Party Expenses 7.14 Trademarks 1.1(bbb) Working Capital Objection Period 2.17(eUnresolved Claims 9.7(b) Working Capital Objection Statement 2.17(eURLs 1.1(bbb) Working Capital Surplus 2.17(f)WEEE Directive 1.1(jj) Year-End Financials 3.7
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gDefined Term Section ACT Section 6.1(a) Agreement Preamble Agreement Date Bardon Hill Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(aBoard Section 3.2(c)(iv) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eCovered Persons Section 4.6(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aNotice Section 5.1(b) Company Preferred Stock 2.10(bROFR Period Section 5.1(b) Company Representative 5.11 Company Software 3.18(lDisqualification Events Section 4.6(a) Company Third Party Consents 6.3(bEffectiveness Period Section 3.4(b) Company Warrant 2.14(aFOD Capital Section 3.9 Founder Preamble Founder Nominees Section 4.2(a) Company Warrant Documents 2.12(aGCM Preamble GIL SPE Preamble Halcyon Preamble HCN Preamble HDML Preamble Holder Violation Section 3.8(b) Confidentiality Initiating Holders Section 3.2(a) KLIM Preamble KLIM Nominee Section 4.2(b) L1 Capital LSF Preamble L1 Global Master Fund Preamble L1 Holders Preamble L1 LSF Limited Preamble Major Investor Preamble Major Investors Preamble MWIG Preamble MWIG Nominees Section 4.2(c) Nominating Committee Section 4.2(d) Nominee Section 4.2(c) Overallotment Notice Section 5.1(e) Participating Stockholders Section 5.1(c) Participating Stockholders’ Overallotment Notice Section 5.1(e) Permitted Assignment Section 6.6 Prior Stockholders’ Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(bRecitals Proposed Transfer Notice Section 5.1(b) Delivered Tax Returns 3.22(aProspective Transferee Section 5.1(a) DGCL Preamble Disclosure Resale Shelf Registration Section 3.4(a) Resale Shelf Registration Statement 5.8(aSection 3.4(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aRight of First Refusal Section 5.1(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(hSecond Proposed Transfer Notice Section 5.1(c) Employee Plan 3.15(hSecondary Refusal Right Section 5.1(c) Employee Welfare Benefit Plan 3.15(hSecondary ROFR Notice Section 5.1(c) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(bShelf Offering Section 3.4(f) Stockholder Approval 3.8 Stockholder Meeting 5.8(bROFR Period Section 5.1(c) Straddle Stockholders Preamble Subsequent Holder Notice Section 3.4(e) Subsequent Shelf Registration Section 3.4(c) Suspension Period 1.1 Subsidiary Securities 3.2(bSection 3.6(a) Survival Date 10.3(aTake-Down Notice Section 3.4(f) Third Party Claim 10.4(bTransfer Shares Section 5.1(a) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fViolation Section 3.8(a)
Appears in 1 contract
Sources: Stockholders’ Agreement (F45 Training Holdings Inc.)
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAdjustment Calculation 2.7(a) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Notice 2.7(a) Agreement Preamble Agreement Date Alcan Preamble Alcan Transaction Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aStatement 2.8(a) Audited Balance Sheet 3.9(bAssignment and Assumption Agreement 2.10(a) Audited Balance Sheet Date 3.9(b) Audited Assumed Liabilities 2.3 Annual Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii3.4(a) ▇▇▇▇▇ Law 3.12(bof Sale 2.10(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bBusiness Preamble Business Information 5.5(b) Straddle Period 1.1 Subsidiary Securities 3.2(bClaim Notice 8.3(a) Survival Closing 2.9 Closing Balance Sheet 2.7(a) Closing Date 10.3(a2.9 Confidentiality Agreement 5.5(a) Consent Decree Preamble Core IP 2.1(f) Core IP Applications Schedule 2.1(f) Customer Loss Event 3.19(a) Customer Reduction 3.19(a) Customer Termination 3.19(a) Deductible 8.5(a) Dispute Notice 2.7(c) Employees 10.1(a) Environmental Deductible 8.5(f) Estimated Closing Net Working Capital 2.6(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Exclusive Grantback IP Schedule 2.1(f) Final Closing Net Working Capital 2.7(a) Financial Statements 3.4(a) Hold Separate Order Preamble Included Contracts 2.1(b) Initial Purchase Price 2.5 Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.6(e) Interim Financial Statement 3.4(a) IP Assignments 2.10(a) Known Environmental Matters 8.5(e) Lease 3.7(b) Leased Real Property 2.1(e) Licensed Intellectual Property Schedule 2.1(f) Marked Assets 5.10(a) Material Contracts 3.9(a) Material Customer 3.19(a) Mixed IP 2.1(f) Mixed IP Applications Schedule 2.1(f) Phase I ESA 8.5(f) Phase II ESA 8.5(f) Pre-Existing Licensee Schedule 2.1(f) Proposal 5.13 Proposed Final Judgment Preamble Purchase Price 2.7(i) Purchased Assets 2.1 Purchased Intellectual Property 2.1(f) Purchaser Preamble Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 8.1 REC 8.5(f) Real Property 3.7 Residual Purchased IP Schedule 2.1(f) Rio Tinto Preamble Savings Plans 3.11(b) Seller Preamble Seller Disclosure Schedule Article 3 Seller Group Preamble Seller Indemnified Parties 8.2 Seller Information 5.10(f) Seller Marks 5.10(a) Surviving Representation 8.4 Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(fTransfer Taxes 9.1(a) Working Capital Objection Period 2.17(eTransferred Employees 10.1(a) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Welfare Plans 10.3
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c1784 Claims Deadline 10.2(a) 280G Payments 6.3(c338(g) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gElection 9.4(h) Adjustment Calculation 2.4(a) Adjustment Notice 2.4(a) Affiliate Indemnified Party 5.14 Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 9.4(c) Alternative Financing 5.5(b) Antitrust Filings 6.2(aLaws 5.3(a) Audited Arbitrator 9.4(c) Assumption Notice 8.3(b) Cinch Contractual Protections 10.5(a)(ii) Cinch Obligation 10.5(a)(ii) Cinch Sites 10.5(a)(ii) Claim Notice 8.3(a) Closing 2.5 Closing Balance Sheet 3.9(b2.4(a) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 2.5 Closing Date Payment 2.2 Closing Failure Notice 7.1(f) Closing Net Cash Statement 2.4(a) Closing Net Working Capital Estimate 2.17(aStatement 2.4(a) COBRA 3.12(c) Commitment Lenders 4.6 Company Preamble Company Board Approval 3.5 CEO 5.12 Company Certificate 2.10(e) Incentive Payments 3.18 Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(aInformation 5.6(b) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b5.6(a) Delivered Tax Returns 3.22(aContinuation Period 11.1(a) DGCL Preamble Disclosure Statement 5.8(aCurrent Sites Claim Deadline 10.2(c) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aDebt Commitment Letter 5.5(c) Effective Time 2.4 Employee Pension Benefit Plan 3.15(hDebt Financing Agreements 5.5(a) Employee Plan 3.15(hDeductible 8.5(a)(ii) Employee Welfare Benefit Plan 3.15(hDeloitte 2.4(e) Dispute Notice 2.4(c)(ii) Election 9.4(a) Environmental Approvals 3.21(eClaims Notice 10.4(a) Environmental Reports 3.21(fIndemnity Control Assumption 10.5(c)(i) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Environmental Indemnity Enforcement Costs 10.5(c)(ii) Environmental Permit 3.14(b)(ii) Environmental Site Relevant Employees 10.9 Estimated Closing Net Cash 2.3(a) Estimated Closing Net Working Capital Surplus 2.17(b2.3(b) FDA Requirements 3.19(aExport Approvals 3.19(b)(i) Final Closing Net Cash 2.4(f) Final Closing Net Working Capital 2.17(e2.4(f) Firm 11.9 FTC 6.2(aFinal Determination 9.4(f) Financial Statements 3.5 Financing 4.6 Financing Extension Date 7.1(f) Financing Failure Fee 7.2(b)(i) Former Sites Aggregate Cap 10.3(a) Former Sites Claims Deadline 10.2(b) FSA Employees 11.2 Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aReps 8.4 Governmental Antitrust Authority 5.3(a) Indemnified D&Os 6.4(aParty 8.3(a) Indemnified Parties 10.1(aIndemnifying Party 8.3(a) Independent Accounting Firm 2.4(e) Initial Purchase Price 2.2 Interim Assumption Notice 8.3(b) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b3.5(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a3.5(b) Leased Property 3.14(aReal Property(ies) Letter Amendment Premable Letter of Transmittal 2.12(a3.8(a) License Lytton Indemnity Process Rights Assignment 10.6(c)(i) Lytton Indemnity Process Rights Assignment Agreement 3.16(a)(xi10.6(c)(i) License Agreements 3.16(a)(xiLytton Indemnity Process Rights Control Assumption 10.6(c)(ii) Majority Effective Time Holders 9.1(cMake Whole Payment 9.4(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(cMaterial Contracts 3.10(a) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(bOriginal Debt Commitment Letters 4.6 Other Former Sites Cap 10.3(a) Outside Date 8.1(b8.5(a)(v) Parent Owned Real Property(ies) 3.8(a) Party Preamble Parent Closing Balance Sheet 2.17(cParties Preamble Property Information 10.8 Purchase Price 2.2 Purchaser Preamble Purchaser FSA 11.2 Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 8.1 Purchaser Welfare Plans 11.2 Qualified Plan 3.12(b) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cReal Property Leases 3.8(a) Parent Working Capital Statement 2.17(cRelated Persons 3.20(a) Paying Agent 2.11(aReleased Parties 5.19 Remediation Notice 10.7 Rep and Warranty Claim 8.5(a) Paying Agent Agreement 2.11(aResolution Period 2.4(e) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(aSEC 5.20 Section 338 Forms 9.4(b) Seller Group 11.19 Series D Stock 1.1 Special Preamble Seller Disclosure Schedule Article 3 Seller Environmental Assessments 3.14(a) Seller FSA 11.2 Seller Indemnified Parties 8.2 Seller Name 5.8(a) Seller Policies 5.10 Seller Rep and Warranty Cap 8.5(a)(iii) Seller Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Article 3 Seller Welfare Plans 11.2 Shares Preamble Termination Date 10.3(a7.1(e) Third Party Claim 10.4(b8.3(a) Working Capital Deficit 2.17(fTransaction Taxes 9.5 TRW Obligation 10.5(a)(i) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fWritten Response 9.4(c)
Appears in 1 contract
Sources: Stock Purchase Agreement (Allied Motion Technologies Inc)
Additional Defined Terms. The In addition to the terms defined in Section 1.1, each of the following terms shall have is defined in the meanings Section set forth on the pages of this Agreement indicated belowopposite such term: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gActual Earnings 2.3(c)(i) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aAnnual Financials 4.6(a) Audited Balance Sheet 3.9(bAnnual Period 2.3(c)(ii) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiAudits 4.9(e) ▇▇▇▇▇ Law 3.12(bPreamble Burdensome Condition 6.3 ▇▇▇▇▇▇▇ Preamble Buyer Preamble Buyer Agreements 5.2 Buyer Disclosure Schedules Preamble to Article V Buyer Indemnitees 8.1 Buyer Losses 8.1 Cap Amount 8.5(c)(iii) Stockholder Approval 3.8 Stockholder Meeting 5.8(bClaim Notice 8.3 Claims Period 8.5(a) Straddle Closing 3.1 Closing Date 3.1 Closing Payment 2.2 Company Recitals Confidentiality 6.8 Cumulative Actual Earnings 2.3(c)(iii) Cumulative Targeted Earnings 2.3(c)(iv) Earn-out Period 1.1 Subsidiary 2.3(c)(v) Execution Date Preamble Final Loss 8.4(e) Financial Statements 4.6(a) First Annual Period 2.3(c)(ii) First Preliminary Statement 2.4(a) Fourth Annual Period 2.3(c)(ii) HUD 4.19 Indemnified Party 8.3 Indemnifying Party 8.3 Leased Real Property 4.17(a)(i) Losses 8.5(d) Material Contracts 4.17(a) Measurement Date 2.3(c)(vi) ▇▇▇▇▇▇▇▇ Preamble Non-Competition, Non-Solicitation and Confidentiality Agreements 3.2(a)(i)(G) Outside Closing Date 9.1(b)(iii) Parties Preamble Personal Data 4.16(b) Pre-Closing Tax Period 8.1(c) Preliminary Statement 2.4(c) Premium Earn-Out Payment 2.3(c)(vii) Premium Earn-Out Payment Date 2.3(c)(viii) Real Property Leases 4.17(a)(i) Related Person 4.8 Representatives 6.6(a) Response Period 8.4(a) Second Annual Period 2.3(c)(ii) Securities 3.2(bAct 5.6 Seller Agreements 4.2 Seller Disclosure Schedules Preamble to Article IV Seller Indemnitees 8.2 Seller Losses 8.2 Sellers Preamble Shares Recitals Split-Dollar Arrangements 4.24(a) Survival Date 10.3(aTargeted Earnings 2.3(c)(ix) Third Annual Period 2.3(c)(ii) Third Party Claim 10.4(bAction 8.4(a) Working Capital Deficit 2.17(fThird Party Action Notice 8.4(a) Working Capital Objection Period 2.17(eTotal Premium Earned 2.3(c)(x) Working Capital Objection Statement 2.17(eTreasury Regulations 4.9(g) Working Capital Surplus 2.17(f)True-Up Payment 2.3(c)(xi) Upfront Premium 2.3(c)(xii) Upfront Premium Allocation 2.3(c)(xiii) USA PATRIOT Act 4.15
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Amount 2.7(g) Agreement Preamble Amadeus Device Preamble Annual Sales Threshold 2.7(d) Anti-Bribery Laws 3.15(a) Assignment and Assumption Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a2.10(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇Assumed Liabilities 2.3 ▇▇▇▇ Law 3.12(bof Sale 2.10(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bClaim Notice 8.3(a) Straddle Closing 2.9 Closing Date 2.9 Closing Payment 2.5 Commercialization Payment 2.6(a) Commercialization Payment Date 2.6(a) Confidentiality Agreement 5.11(a) ConvaTec Preamble CTI Preamble Deductible 8.5(a) Defaulting Party 2.11 Equipment 2.1(c) Excluded Assets 2.2 Excluded Liabilities 2.4 FDA 3.11 FDCA 3.11(a) Financial Buyer 5.6(d) Included Contracts 2.1(b) Initial Sales Payment Period 1.1 Subsidiary Securities 3.2(b2.7(a) Survival Initial Sales Percentage Amount 2.7(a) Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.7(f) Insurance Policy 5.8 Inventory 2.1(a) Large Acquisition 5.6(c) Non-Financial Buyer 5.6(d) Non-SMM Product Sales 2.7(a) Parent Preamble Patent Assignment 2.10(a) Payment Date 10.3(a2.14(a) Percentage Payments Determination Report 2.7(e) Percentage Payments Period 2.7(c) Permitted Acquisition 5.6(c) PPDR 2.7(e) Project Preamble Project Information 5.11(b) Purchase of a Restricted Business 5.6(c) Purchase Price 2.5 Purchased Assets 2.1 Purchased Intellectual Property 2.1(d) Purchaser Preamble Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 8.1 Purchaser Information 5.4(e) Restricted Period 5.6(a) Relevant Acquisition 5.6(c) Sales Payment Period 2.7(c) Sales Percentage Amount 2.7(c) Seller Preamble Seller Disclosure Schedule Article 3 Seller Facility 2.12 Seller Indemnified Parties 8.2 Seller Information 5.4(d) Seller Marks 5.4(a) Seller Sale 5.6(d) Sellers Preamble SMM Platform Preamble SMM Product Sales 2.7(a) Software Assignment 2.10(a) Successor 5.9 Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Transfer Taxes 5.15
Appears in 1 contract
Sources: Asset Sale and Purchase Agreement (Tactile Systems Technology Inc)
Additional Defined Terms. The In addition, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) Disclosure 5.4 280G Payments 6.3(c5.4 280G Stockholder Vote 5.4 ABC Consulting 2.10(f) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gABC Notes 1.1 Administrative Costs 11.19(a) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Assumptions 4.6 Audited Balance Sheet 3.9(b) Audited Sheets 3.5 Balance Sheet Date 3.9(b3.5 Base Consideration 2.2 Business Systems 3.14(d) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Buyer Preamble Buyer Parties Preamble Certificate of Merger 2.4 2.3 Chosen Courts 11.7 Claims 10.4 CLIA 1.1 6.4(d) Closing 2.4 2.9(a) Closing Date 2.4 2.9(a) Closing Working Capital Estimate 2.17(aOption Consideration 2.7(c)(i) Closing Payment Spreadsheet 2.8(b) Closing RSU Consideration 2.7(c)(iii) Closing Statement 2.10(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eEmployees 6.6(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aIntellectual Property Assets 3.14(d) Company Preferred Stock 2.10(bSubsidiary 3.3 Company Transaction Expense Amount 2.2(g) Company Representative 5.11 Company Software 3.18(lContracting Party 11.15 Copyrights 3.14(d)(iii) Company Third Party Consents 6.3(bD&O Indemnified Parties 6.4(a) Company Warrant 2.14(aData Security Laws 3.14(d) Company Warrant Documents 2.12(aDebt Financing 6.12 Debt Payoff Amount 2.8(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(bDisputed Items 2.10(c) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(aDissenting Holders 2.7(b)(iii) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a2.7(b)(iii) DGCL Recitals Effective Time 2.4 Employee Pension Benefit Plan 3.15(h2.3 End Date 10.1(b) Employee Plan 3.15(hERISA 3.11(c) Employee Welfare Benefit Plan 3.15(hEstimated Closing Statement 2.9(b) Environmental Approvals 3.21(eEstimated Merger Consideration 2.9(b) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) Financial Statements 3.5 Governmental Body 3.4 HSR Act 6.2(a3.4 Independent Accounting Firm 2.10(c) Indemnified D&Os 6.4(aIntellectual Property Assets 3.14(d) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Joinder Agreement Recitals Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(aMarks 3.14(d)(ii) Payment Fund 2.11(aMerger Recitals Merger Consideration 2.2 Merger Sub Preamble Nonparty Affiliates 11.15 Patents 3.14(d)(i) Payoff Letters 2.8(a) Permits 3.17(a) Personal Information 3.14(d) Post-Closing Plans 6.6(b) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a5.1(a) Preliminary Closing Statement 2.17(aProjections 9.3(b) Prior Merger Agreement Protest Notice 2.10(c) Real Property Lease 3.12(c) Releasee 6.4(d) Releasor 6.4(d) Requisite Stockholder Approval Recitals RSU Holders 2.9(b) Schedules 11.2 Seller Representative Preamble Related Agreements 3.5(aSignificant Contracts 3.13 Significant Customer 3.19(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(bSignificant Supplier 3.20(a) Stockholder Approval 3.8 Consent Recitals Stockholder Meeting 5.8(bDebt Amount 2.2(d) Straddle Period 1.1 Subsidiary Securities 3.2(bSurviving Company Recitals Tax Returns 3.10(a) Survival Date 10.3(aTaxes 3.10(a) Taxing Authority 3.10(a) Third Party Claim 10.4(bRights 3.14(a)(iii) Working Capital Deficit 2.17(fTrade Secrets 3.14(d)(iv) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Waived 280G Benefits 5.4
Appears in 1 contract
Sources: Merger Agreement (Concentrix Corp)
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAdjustment Calculation 2.7(a) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Notice 2.7(a) Agreement Preamble Assignment and Assumption Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a2.10(a) Audited Assumed Liabilities Section 2.3 Balance Sheet 3.9(b3.5(a) Audited Balance Sheet Date 3.9(b▇▇▇▇ of Sale 2.10(a) Audited Financial Statements 3.9(bClaim Notice 9.3(a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent 2.9 Closing Balance Sheet 2.17(c2.7(a) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cClosing Date 2.9 COBRA 3.16(c) Parent Working Capital Statement 2.17(cCompeting Activity 8.7(a) Paying Agent 2.11(aConsulting Agreement 2.10(a) Paying Agent Agreement 2.11(aControlling Party 9.4(c) Payment Fund 2.11(aDispute Notice 2.7(b) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiDOL 3.16(b) ▇▇▇▇▇▇▇ Law 3.12(bMoney Deposit 2.13(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(bEmployment Agreements 2.10(a)
(a) Straddle Period 1.1 Subsidiary Escrow Agent 2.10
(a) Estimated Balance Sheet 2.6(a) Estimated Closing Net Working Capital 2.6(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Final Closing Net Working Capital 2.7(a) Financial Statements 3.5(a) Hired Employee 8.12(a) Improvements 3.12(d) Indemnified Party 9.3(a) Indemnifying Party 9.3(a) Independent Accounting Firm 2.7(d) Initial Purchase Price 2.2 Interim Balance Sheet 3.5(a) Leased Real Property 2.1 Multiemployer Plan 3.16(c) Noncontrolling Party 9.4(c) Objection Notice 9.3(b) Owned Intellectual Property 3.13(a) Owned Real Property 2.1(a) Pension Plan 3.16(b) Permitted Exceptions 5.7(c) Purchase Price 2.7(h) Purchased Assets 2.1 Purchaser Disclosure Schedule Article 4 Purchased Intellectual Property 2.1 Purchaser Preamble Purchaser Indemnified Party 9.1 Qualified Plan 3.16(b) Real Property Permits 3.12(f) Recorded Documents 5.7(a) Restricted Persons 8.4(b) Securities 3.2(bAct 3.4(d) Survival Date 10.3(aSeller Preamble Seller Disclosure Schedule Article 3 Seller Real Property 3.12 Members Preamble Selling Parties Representative 10.1 Special Claim 9.4(b) Survey 5.7(a) Tangible Personal Property 2.1 Third Party Claim 10.4(bIntellectual Property 3.13(b) Working Capital Deficit 2.17(fTitle Commitment 5.7(a) Working Capital Title Cure Period 5.7(c) Title Defect 5.7(c) Title Insurer 5.7(a) Title Objection Period 2.17(eNotice 5.7(c) Working Capital Objection Statement 2.17(eTitle IV Plan 3.16(c) Working Capital Surplus 2.17(fTransfer Taxes 8.1(a)
Appears in 1 contract
Sources: Asset Purchase Agreement (Nova Biosource Fuels, Inc.)
Additional Defined Terms. The As used herein, the following terms shall have the meanings set forth on defined in the pages of this Agreement recitals or sections indicated below: 280G Approval 6.3(cAccess Indemnified Parties Section 3.01(b) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdditional Seller Section 11.02(a) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Alternative Transaction Section 2.01 Closing 2.4 Section 11.01 Closing Date 2.4 Section 3.03 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Distribution Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Section 2.02 Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiSection 11.02(a)(v) ▇▇▇▇ Opco Recital F ▇▇▇▇ Law 3.12(bOpco II Recital G Due Diligence Materials Section 3.01(c) Stockholder Approval 3.8 Stockholder Meeting 5.8(bFacilities Recital G Failure of Condition Notice Section 13.02(c) Straddle Period 1.1 Subsidiary Securities 3.2(bGP Recital A GP Agreement Recital C Guaranty Section 10.02(d) Survival Date 10.3(aHoldco Recital E Holdco Carecos Recital J Holdco Facilities Recital F Holdco Opcos Recital H Holdco Propcos Recital F Holdco II Recital E Holdco II Carecos Recital J Holdco II Facilities Recital G Holdco II Opcos Recital I Holdco II Propcos Recital G Indemnified Party Section 12.06(a) Third Indemnifying Party Claim 10.4(bSection 12.06(a) Working Capital Deficit 2.17(fLoan Modification Section 4.02 LP Recital A LP Agreement Recital D Manager Recital K Mutual Release Section 11.02(a)(vii) Working Capital MSREF-A Preamble MSREF-B Preamble MSREF-T Preamble MSREF-TE Preamble MSREF Investors-VI Preamble Newco Transaction Section 4.01 Purchaser Preamble Purchaser Default Notice Section 13.02(b) Purchase Price Section 2.01(d) Purchaser’s Objection Period 2.17(eNotice Section 13.02(b) Working Capital Seller Preamble Seller Default Notice Section 13.02(a) Seller’s Interest Recital A Seller’s Failure of Condition Objection Statement 2.17(eNotice Section 13.02(c) Working Capital Surplus 2.17(f)Seller’s Objection Notice Section 13.02(a) Term Sheet Section 4.02
Appears in 1 contract
Sources: Purchase and Sale Agreement (Sunrise Senior Living Inc)
Additional Defined Terms. The following terms shall have the meanings meaning assigned to such terms in the Sections of the Agreement set forth on the pages of this Agreement indicated below: 280G Approval 6.3(cAccounting Firm 2.6 Acquisition Transaction Recitals Aggregate Earnout Period 2.5(a) 280G Payments 6.3(cAllowable Grace Period 5.15(a)(vi) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAnnual Earnout Period 2.5(a) Agreement Preamble Introductory Paragraph Asset Purchase Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Recitals Balance Sheet 3.9(b3.5(a) Audited Balance Sheet Date 3.9(b3.5(a) Audited Base Purchase Price 2.2(a)(i) Basic Earnout 2.5(b) Benefit Plans 3.16(b) Bonus Earnout 2.5(b) ClearOne Introductory Paragraph Closing 2.7 Closing Adjustment Statement 2.5 Closing Payment Amount 2.2(b) Direct Claim 8.5(c) 11 Earnout Payment Statement 2.5(b) Escrow Fund 2.3 Escrow Payment 2.5(a) Estimated Net Assets Statement 2.2(a)(ii) Effectiveness Deadline 5.15(a) Filing Deadline 5.15(a) Financial Statements 3.9(b3.5(a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Foreign IP Transaction Recitals Fundamental Representations 10.2(a)(ii8.1 HK Note Recitals HK Purchaser Recitals Inadvertent Termination Ruling 5.5(h) HSR Act 6.2(aInadvertent Termination Ruling Request 5.5(h) Indemnification Period 8.1 Indemnified D&Os 6.4(aParty 8.5 Indemnifying Party 8.5 Initial Net Asset Adjustment Amount 2.2(a)(ii) Indemnified Lease Transaction Recitals Material Contracts 3.13 Material Customers 3.21(a) Material Suppliers 3.21(b) Net Asset Adjustment Amounts 2.2(a)(ii) Party or Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Introductory Paragraph Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a5.6 Purchase Price Adjustment 5.5(d) Preliminary Closing Purchase Price 2.2(a) Purchaser Introductory Paragraph Purchaser’s Agents 5.15(g)(ii) Purchaser Indemnitees 8.2 Quarterly Earnout Period 2.5(b) Real Estate Entity Recitals Registration Expenses 5.15(a)(iv) Registration Statement 2.17(a5.15(a) Prior Merger Agreement Preamble Related Agreements 3.5(aRegistration Termination Date 5.15(a) Registry Recitals Sabine Recitals Sabine Business Recitals Sabine Database 3.12(h) Sabine Net Revenue Schedule 2.4(d) Section 338(h)(10) Election 5.5(d) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiIntroductory Paragraph Seller’s Agents 5.15(g)(i) Specified Representations 10.2(a)(iiiSelling Expenses 5.15(a)(iv) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(aShares Recitals Statement of Objections 2.6 Tax Adjustment 5.5(d) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f8.5(a)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cDefined Term Section Accounts Receivable 2.1(b)(ii) 280G Payments 6.3(cAccrued Payroll and Benefits 2.4(e) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAcquired Company Intellectual Property 3.10 Acquired Company Leased Real Property 3.9(b) Acquired Company Real Property 3.9(a) Adjustment Calculation 2.6(a) Adjustment Notice 2.6(a) Affiliate Indemnified Party 5.12 Agreement Preamble Approval Notification 11.4(f) Approval Order Defined Term Section Approval Order 5.3(a) Artek Preamble Assignment and Assumption Agreement Date 2.9(a)(ii) Assumed Liabilities 2.3 Aterian Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aBankruptcy Avoidance Actions 2.2(m) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiBidding Procedures Order 5.3(a) ▇▇▇▇▇ Law 3.12(bof Sale 2.9(a)(i) Stockholder Approval 3.8 Stockholder Meeting 5.8(bBonus Payments 10.1(e) Straddle Business Information 5.9(b) Business Intellectual Property Rights 3.10 Calculation Principles 2.6(a) Chosen Court 12.13 Ciba Environmental Indemnity Assignment 2.9(a)(xiii) Claim Notice 8.3(a) Closing 2.8 Closing Allocation Schedule 2.7 Closing Date 2.8 Commitment Letters 4.7 Confidentiality Agreement 5.9(a) Continuation Period 1.1 Subsidiary Securities 3.2(b10.1(c) Survival Date Controlling Party 8.3(d) Control Notice 11.4(b) Deposit Agent 2.5(b)(i) Deposit Amount 2.5(b)(i) Dispute Notice 2.6(c)(ii) Environmental Authorizations 3.15(a) European Trade Accounts Payable 2.4(c) Excluded Assets 2.2 Excluded Intellectual Property 2.2(h) Excluded Liabilities 2.4 Final Cash Consideration 2.5(a) Final Closing Net Working Capital 2.6(a) Financial Statements 3.5 German GAAP Financial Statements 5.22(b) Governmental Antitrust Authority 5.5(a) Initial Allocation Schedule 2.7 Included Contracts 2.1(b)(iii) Income Statement 3.5 Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.6(f) Independent Consultant 11.4(g) Initial Allocation Schedule 2.7 Initial Cash Consideration 2.5(a) Inventory 2.1(b)(i) Inventory Cap 2.6(b) Defined Term Section IP Assignments 2.9(a)(v) IP License Agreement 2.9(a)(v) Isopetronate HL-44 Toll Manufacturing Agreement 5.21 Latin American Purchased Assets 2.10(d) Lease 3.9(b) Loss Compensation Claim 5.22(b) Marked Assets 5.15(b) Material Contracts 3.11(a) New Defined Benefit Plan 10.2(a) Non-Controlling Party 8.3(d) Off-Site Liabilities 2.4(k) Other Purchased Assets 2.10(a) Owned Real Property 2.1(b)(v) Pension Plan 10.2(a) Plan Assets Amount 10.2(b) Profit Transfer Claim 2009 5.22(b) Purchase Price 2.5(a) Purchased Assets 2.1(b) Purchased Intellectual Property 2.1(b)(vi) Purchaser Preamble Purchaser Indemnified Parties 8.1 Regulation 3.22 Sale Motion 5.3(a) Savings Plan 10.3(a) Seller Preamble Seller Disclosure Schedule Article 3 Seller Indemnified Parties 8.2 Seller Information 5.15(f) Seller Marks 5.15(a) September ’09 Net Assets Statement 3.5 Share Transfer Agreement 2.9(a)(iii) Shared Accounts Payable 2.4(d) TBT Supply Agreement 2.9(a)(x) TOT Supply Agreement 2.9(a)(xi) TNPP Supply Agreement 5.21(a) TPP/LPE Supply Agreement 2.9(a)(xii) Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(fThreshold 8.5(a)(ii) Working Capital Objection Period 2.17(eTrade Accounts Payable 2.4(b) Working Capital Objection Statement 2.17(eTransferred Employee 10.1(b) Working Capital Surplus 2.17(f)Transfer Taxes 9.1(e) Transferred Employee 10.1(b) Transition Services Agreement 2.9(a)(ix) Welfare Plan 10.4 Weston 705 Supply Agreement 5.21
Appears in 1 contract
Additional Defined Terms. The As used herein the following terms shall have the meanings set forth on in the pages of this Agreement preamble, recital or section indicated below: 280G Approval 6.3(c$10B HCREIT 2.3 15% Calculation 6.1(iii) 280G Payments 6.3(c2008 Letter Agreement Recital A 2009 Letter Agreement Recital A 7% Capped Calculation 6.1(iv) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAAA 15.1(a) Accrued But Not Yet Due Fees and Expenses Reimbursements 18.3 Affected Management Agreement 7.1(d) Aggregate Cure Limit 3.5(a) Aggregate Expense Overage 3.4 Aggregate Expense Overage Amount 3.4 Aggregate Expense Overage Cure 3.4 Aggregate Expense Termination Right 3.4 Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aAll Facilities Actual Percentage 7.2.3(b) Audited Balance Sheet 3.9(bANOI Testing Date 3.1.1 Applicable BMF Percentage 5.2 Applicable Lenders 18.4 Applicable Period 7.2.3(b) Audited Balance Sheet Arbitrable Dispute 15.1(a) Arbitration Notice 15.1(a) Beneficiaries 16.1 BMF Continuing Facility Adjustment Factor 7.2.3(a) BMF/IMF Continuing Facility Percentage 7.2.3(a) BMF Transferred Facility Adjustment Factor 7.2.3(a) BMF/IMF Transferred Facility Percentage 7.2.3(a) Canadian Budget Percentage 3.4.1(a) Continuing Facilities 7.2.1(a) Continuing Facility Actual Percentage 7.2.3(b) Event of Default 15.1 Existing Facilities Recital B Existing Immediate or Unmatured Event of Default 18.5(a) Existing Loan Document 18.4 Existing Management Agreement Recital C Existing Master Agreement Recital A Existing Owners Recital B Existing Ventas/Sunrise Agreements 18.2 Expense Termination Right 3.4 Facility Cessation Date 3.9(b7.2 Facility Cure Limit 3.2.2 Facility Expense Overage Cure 3.3 Facility Expense Termination Right 3.3 Facility Performance Cure Amount 3.4(ii) Audited Financial Statements 3.9(bIMF Continuing Facility Adjustment Factor 7.2.3(a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(aIMF Transferred Facility Adjustment Factor 7.2.3(a) Letter Amendment Premable Letter of Transmittal 2.12(aAgreements Recital A Management Group 18.3 Monetary Failure Notice 15.1(a) License Agreement 3.16(a)(xi) License New Facilities Recital D New Management Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Recital D New PSF Owners Recital E New Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(aStabilized Facility Recital E New SF Owners Recital E New Stabilized Facility Recital E Other Section 3.2.3 Termination Rights 3.2.3(iii) Preliminary Closing Statement 2.17(aPayment/Credit-Back 15.1(a) Prior Merger Property Performance Cure 3.2 Property Performance Termination Right 3.1 REIT 14 Related Agreement Preamble SSLI Event of Default/ Termination Right 18.4 Related Agreements 3.5(a18.3 Released Matters 18.4 Residents 2.1(b) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiRestated Management Agreement Recital C SEC 18.5(c) Specified Representations 10.2(a)(iiiSection 2.3 Person 2.3 Section 3.2.3 Month 3.2.3 Section 3.2.3 Period 3.2.3(i) ▇▇▇▇▇ Law 3.12(bSection 3.2.3 Termination Right 3.2.3 Section 3.2.3 Waiver 3.2.3 Severed Master Agreement 7.2.2(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bShared Expenses Continuing Facilities Factor 7.2.3(b) Straddle Shared Expenses Percentage 4 Shared Expenses Transferred Facilities Factor 7.2.3(b) Significant Actual Prejudice 18.5(a) SOX 2.5 SSLI Preamble Successor Owner/Lessee 7.1(b) Successor Parent Owner/Lessee 7.1(c) Sunrise Parties 2.3 Terminated Facility 5.5 Terminated Management Agreement 5.5 Termination Effective Date 5.5 Total Facility Overage Payments Amount 3.4(i) Total Performance Cure Amount 3.4(ii) Trailing Twelve Month Period 1.1 Subsidiary Securities 3.2(b7.2.3(a) Survival Date 10.3(aTransferred Facility 7.1(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fTransferred Facilities 7.1(c)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAdjustment Calculation 2.7(a) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Notice 2.7(a) Agreement Preamble Annual Earn-out Payment 2.8(d) Annual Earn-out Period 2.8(a) Arbitrating Accountant 2.9(a) Assignment and Assumption Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a2.12(a) Audited Associate 3.26 Assumed Liabilities 2.3 Balance Sheet 3.9(b3.5(a) Audited B▇▇▇ of Sale 2.12(a) Claim Notice 9.3(a) Closing Balance Sheet Date 3.9(b2.7(a) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a2.11 COBRA 8.13(d) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b8.4(a) Delivered Tax Returns 3.22(aControlling Party 9.4(c) DGCL Preamble Disclosure Statement 5.8(aDispute Notice 2.7(b) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aEarn-out Calculation 2.8(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(hEconomically Neutral 2.13(b) Employee Plan 3.15(hEmployment Agreements 2.12(a) Employee Welfare Benefit Plan 3.15(hEstimated Closing Balance Sheet 2.6(a) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Closing Net Working Capital Surplus 2.17(b2.6(a) FDA Requirements 3.19(a) Excluded Assets 2.2 Excluded Liabilities 2.4 Final Closing Net Working Capital 2.17(e2.7(a) Firm 11.9 FTC 6.2(aFinancial Statements 3.5(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aHired Employee 8.13(a) Indemnified D&Os 6.4(aParty 9.3(a) Indemnified Parties 10.1(aIndemnifying Party 9.3(a) Initial Purchase Price 2.5 Interim Balance Sheet 3.9(b3.5(a) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(aIP Assignments 2.12(a) Leased Real Property 3.14(a3.12(b) Letter Amendment Premable Letter of Transmittal 2.12(aNoncontrolling Party 9.4(c) License Agreement 3.16(a)(xiObjection Notice 9.3(b) License Agreements 3.16(a)(xiOwned Intellectual Property 3.13(a) Majority Effective Time Holders 9.1(cPurchase Price 2.5 Purchased Assets 2.1 Purchased Intellectual Property 2.1 Purchaser Preamble Purchaser Indemnified Parties 9.1 Qualifying Gross Margin Dollars Schedule 2.8(g) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(cQualified Plan 3.16(e) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(bRestrictive Period 8.8(d) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(aRestricted Persons 8.4(b) Seller Group 11.19 Series D Stock 1.1 Preamble Seller Disclosure Schedule Article 3 Selling Parties’ Representative 10.1 Shareholders Preamble Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(aClaim 9.4(b) Third Party Claim 10.4(b9.4(a) Working Capital Deficit 2.17(fThird Party Intellectual Property 3.13(c) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fTransfer Taxes 8.1(a)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAcquisition and Disposition Fee Shortfall 3.4(a)(i) 280G Payments 6.3(cActual Closing Balance Sheets 3.2(b) Acquisition Proposal 5.11 Acquisition Sub Actual Closing Date Cash 3.2(b) Actual Closing Date Unpaid Indebtedness 3.2(b) Actual Closing Date Unpaid Transaction Expenses 3.2(b) Actual Closing Date Working Capital 3.2(b) Additional Indemnitor Preamble Additional Indemnitors Preamble Agreed Claims 10.4(gAdjustments 3.2(d) Agreement Preamble Agreement AHI Preamble AHI Disclosure Letter 5 AHI Principals Preamble Assumed Liabilities 2.1(d) Basket 11.4(a) Business Intellectual Property 5.15(a) Cap 11.4(a) Change of Recommendation 8.9 Claim 11.5(a) Closing 4.1 Closing Contribution 3.1 Closing Date 4.1 Colony Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aConsolidated Entities 5.11(a) Audited Balance Sheet 3.9(bContributed Assets 2.1(b) Audited Balance Sheet Covered Persons 8.11(c) Current Fee Participation Amount 3.4(a)(ii) Current Fee Participation Payment 3.4(a)(iii) Data Room 12.1(a) Dispute Period 3.4(f) DLA 12.1(a) Earnout Clawback 3.4(b) Earnout Consideration 3.4(b) Earnout Consideration Statement 3.4(e) Earnout Period 3.4(a)(iv) Estimated Closing Date 3.9(bCash 3.2(a) Audited Estimated Closing Date Unpaid Indebtedness 3.2(a) Estimated Closing Date Unpaid Transaction Expenses 3.2(a) Estimated Closing Date Working Capital 3.2(a) Estimated Closing Statement 3.2(a) Final Adjustment Amount 3.2(e) Final Closing Date Value 3.2(e) Financial Statements 3.9(b5.11(a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing First Minimum Funding Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii3.4(c) ▇▇▇▇▇▇▇▇ Law 3.12(bTrust Preamble FLSA 5.10(j) Fund Carried Interest 3.4(a)(v) Fund Costs 3.4(a)(vi) Fund Management Fees 3.4(a)(vii) Fund Placement Fees 3.4(a)(viii) Fund Transaction Fee Adjustment 3.4(a)(ix) Fundamental Representations 11.1 ▇▇▇▇ III Preamble ▇▇▇▇ III Board Recitals ▇▇▇▇ III Capital Contributions 3.4(a)(x) ▇▇▇▇ III Common Stock 7.5(a) ▇▇▇▇ III Indemnified Persons 11.3 ▇▇▇▇ III OP Preamble ▇▇▇▇ III Preferred Stock 7.5(a) ▇▇▇▇ IV Recitals ▇▇▇▇ IV OP Recitals ▇▇▇▇ Plans 8.15(b) Government Entity 5.20(b) GP Claw-Back 3.4(a)(xi) GP Indemnification Costs 3.4(a)(xii) ▇▇▇▇▇▇▇ Capital Preamble HoldCo Recitals HoldCo to NewCo Pre-Closing Contributions 2.1(b) Imputed Fee Generation Amount 3.4(a)(xiii) Independent Directors 3.4(e) Leased Real Property 5.16(a) Material Contracts 5.13(a) Merger Agreement Recitals Merger Exchange Ratio Recitals Merger Sub Recitals NewCo Recitals NewCo Interests Recitals Notice of Disagreement 3.4(f) Objection 3.2(d) Objection Notice 3.2(c) OP Merger Recitals Offer Employee 8.15(a) Offer Letter 8.15(a) Personal Information 5.22 Post-Closing Statement 3.2(b) Post-Merger OP Operating Agreement Recitals Pre-Merger OP Operating Agreement Recitals Proxy Statement 8.8(a) Real Property Leases 5.16(a) Recommendation 7.2(b) REIT Merger Recitals Requisite ▇▇▇▇ III Stockholder Approval 3.8 Stockholder Meeting 5.8(b7.2(a) Straddle Period 1.1 Subsidiary Securities 3.2(bRetained Assets 2.1(c) Survival Date 10.3(aRetained Liabilities 2.1(e) Special Committee Recitals Sponsor Preamble Sponsor Indemnified Persons 11.2 Sponsor Indemnifying Parties 11.3 Sponsor Representative Agreement 12.4(b) Sponsor to HoldCo Pre-Closing Contributions 2.1(a) Sponsors Preamble Third Party Claim 10.4(b11.6(a) Working Total Consideration 3.1 Transferred Books and Records 2.1(b)(iv) Unreturned ▇▇▇▇ III Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fContributions 3.4(a)(xiv)
Appears in 1 contract
Sources: Contribution Agreement (Griffin-American Healthcare REIT III, Inc.)
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAAP Assets 2.6(a) 280G Payments 6.3(cAdjustment Calculation 2.4(a) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Notice 2.4(a) Agreement AGIP First Paragraph AGIP Sellers Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited First Paragraph Balance Sheet 3.9(b3.5(a) Audited Cap 7.6(a) Certain Nations 3.19(f) Claim Amount 7.6(a) Claim Notice 7.3(a) Class A Shares 3.4(a) Class B Shares 3.4(a) Closing 2.5 Closing Balance Sheet Date 3.9(b2.4(a) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a2.5 Company First Paragraph Company Intellectual Property 3.12(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eCompeting Activity 5.3(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(aConfidential Information 5.2(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b5.2(a) Delivered Tax Returns 3.22(aControlling Party 7.4(f) DGCL Convertible Debt Assignment and Transfer Documents 2.6(a) Covered Claims Schedule G Disputed Amount 7.7(c) Dispute Notice 2.4(b) [***] = Confidential Treatment requested for redacted portion; redacted portion has been filed separately with the Commission. Earnout Amount Schedule C Earnout Participants Schedule C Employee IP Assignment and Release Agreements 2.6(a) Employment Agreements 2.6(a) Equity Interests Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(fEquity Transfer Documents 2.6(a) Escrow Agent 2.16 2.6(a) Escrow Agreement 2.16 2.6(a) Escrow Amount 2.6(c) Escrow Fund 2.16 2.7 Estimated Working Capital Surplus 2.17(bClosing Balance Sheet 2.3 [***] 2.4(a) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aFinancial Statements 3.5(a) Indemnified D&Os 6.4(aParty 7.3(a) Indemnified Parties 10.1(aIndemnifying Party 7.3(a) Indemnity Determination Date 7.3(h) Indemnity Final Determination 7.3(h) Indemnity Interest Amount 7.7(b) Independent Accounting Firm 2.4(d) Initial Purchase Price 2.2 Interim Balance Sheet 3.9(b3.5(a) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(aKey Employees 3.9(j) Leased Real Property 3.14(a3.11(b) Letter Amendment Premable Letter of Transmittal 2.12(aMembership Interests Preamble Non-Controlling Party 7.4(f) License Agreement 3.16(a)(xiObjection Notice 7.3(b) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(cAgreements 2.6(a) Organizational Option Share Transfer Documents 3.3 Out-of-the-Money Company 2.6(a)
(a) Parity Option 2.13(bAssignment and Transfer Documents 2.6(a) Out-of-the-Money Company Warrant 2.14(bPerformance Share Unit Agreements 2.6(a) Outside Purchase Price 2.2 Priceline US First Paragraph Pro Rata Portion Schedule C Purchasers First Paragraph Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 7.1 Released Earnout Amount 7.7(c) Restricted Stock Unit Agreements 2.6(a) Scheduled Earnout Payment Date 8.1(b7.7(c) Parent Preamble Parent Closing Balance Sheet 2.17(cSecurities Act 3.4(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(aSellers First Paragraph Seller Disclosure Schedule Article 3 Seller Releases 2.6(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiRepresentative 8.1(a) Specified Representations 10.2(a)(iiiShares Preamble Share Purchaser First Paragraph Share Sellers Preamble Share Transfer Forms 2.6(a) ▇▇▇▇▇ Law 3.12(bThird-Party Claim 7.4(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bThird-Party Claim Notice 7.4(a) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) [***] = Confidential Treatment requested for redacted portion; redacted portion has been filed separately with the Commission. Third Party Claim 10.4(bIntellectual Property 3.12(c) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fThreshold 7.6(a)
Appears in 1 contract
Additional Defined Terms. The following terms shall have are defined in the meanings respective Sections set forth on the pages of this Agreement indicated below: 280G Approval 6.3(cAgreement Recitals Annual Financial Statements 5(b)(i)(A) 280G Payments 6.3(cAssumed Liabilities 3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gBuyers Recitals Buyer Group Recitals Cap 11(d)(ii) Cash Consideration 4(b)(i)(C) Closings 4(a) Debt Engagement Letter 6(b)(v) Department of Revenue 7(ff) Equity Engagement Letters 6(b)(v) Ethanex Recitals Ethanex Recommendation Change 7(x)(iv) Ethanex Schedules 6(b) Ethanex SEC Documents 6(b)(iv) Ethanex Stockholder Meeting 7(x)(iii) Exchange Act 6(b)(iv) Extended Phase II Deadline 7(j)(iii) Extended Phase III Deadline 7(k)(iii) Excluded Assets 2(d) Excluded Liabilities 3(d) Existing Plant Recitals Financing Documents 7(r)(iv) Financing Letters 6(b)(v) Fractionation Plant 7(aa) Hired Employees 7(m) Indemnitee 11(c)(i) Indemnitor 11(c)(i) Indemnity Escrow Account 4(b)(iii)(B) Independent Accountant 4(d)(i)(A) Investor Rights Agreement Preamble 9(c)(v) Inventory Adjustment Reports 4(d)(iii)(A) JV Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a7(w) Audited Latest Balance Sheet 3.9(b5(b)(i)(A) Audited Balance Sheet Date 3.9(b) Audited Latest Financial Statements 3.9(b5(b)(i)(A) California Stockholder Approval 3.8 Loop Real Property 9(b)(vi) Losses 11(b)(i) Material Consents 9(a)(i) Material Contracts 5(b)(vii) Minimum Loss 11(d)(i)(A) Monthly Financials 7(r)(i) Negative Phase II Net Cost Amount 1(a)(xxxviii) Negative Phase III Net Cost Amount 1(a)(xxxix) Net Cost Adjustment Reports 4(d)(iii)(B) Owned Real Property Recitals Owned Real Property Funded Debt 7(p) Permits 5(b)(xiii) Permitted Encumbrances 5(b)(iv)(K) Phase I Assets Recitals Phase I Assumed Liabilities 3(a) Phase I Buyer Recitals Phase I Closing 4(a) Phase I Closing Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 7(p) Phase I Closing Date 2.4 4(a) Phase I Escrow Amount 4(b)(iii)(C) Phase I Financing Condition 9(b)(iv) Phase I Funded Debt 7(p) Phase I Inventory Adjustment Report 4(d)(i)(A) Phase I Inventory Objection Notice 4(d)(i)(A) Phase I Purchase Price 4(b)(i)(A) Phase I Termination Date 12(a)(ii) Phase II Assets Recitals Phase II Assumed Liabilities 3(b) Phase II Buyer Recitals Phase II Cash Consideration 4(b)(i)(B) Phase II Closing Working Capital Estimate 2.17(a4(a) Company Preamble Company Board Approval 3.5 Company Phase II Closing Certificate 2.10(e7(p) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aPhase II Closing Date 4(a) Company Preferred Phase II Completion Cost 4(b)(ii)(A) Phase II Completion Date 4(b)(ii)(A) Phase II Escrow Amount 4(b)(iv)(B) Phase II Funded Debt 7(p) Phase II Deadline 4(b)(ii)(A) Phase II Inventory Adjustment Report 4(d)(ii)(A) Phase II Inventory Objection Notice 4(d)(ii)(A) Phase II Net Cost Adjustment Report 4(d)(ii)(B) Phase II Net Cost Objection Notice 4(d)(ii)(B) Phase II Premium 4(b)(ii)(A) Phase II Purchase Price 4(b)(i)(B) Phase II Stock 2.10(bConsideration 4(b)(i)(B) Company Representative 5.11 Company Software 3.18(lPhase III Adjustment 4(b)(ii)(C) Company Third Party Consents 6.3(bPhase III Assets Recitals Phase III Assumed Liabilities 3(c) Company Warrant 2.14(aPhase III Buyer Recitals Phase III Cash Consideration 4(b)(i)(C) Company Warrant Documents 2.12(aPhase III Closing 4(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(bPhase III Closing Certificate 7(p) Delivered Tax Phase III Closing Date 4(a) Phase III Completion Cost 4(b)(ii)(C) Phase III Completion Date 4(b)(ii)(C) Phase III Deadline 4(b)(iii)(C) Phase III Escrow Amount 4(b)(v)(B) Phase III Funded Debt 7(p) Phase III Inventory Adjustment Report 4(d)(iii)(A) Phase III Inventory Objection Notice 4(d)(iii)(A) Phase III Net Cost Adjustment Report 4(d)(iii)(B) Phase III Net Cost Objection Notice 4(d)(iii)(B) Phase III Premium 4(b)(ii)(C) Phase III Purchase Price 4(b)(i)(C) Phase III Stock Consideration 4(b)(i)(C) Plan or Plans 5(b)(x)(A) Positive Phase II Net Cost Amount 1(a)(xxxviii) Positive Phase III Net Cost Amount 1(a)(xxxix) Purchase Price 4(b)(i) RE LLC Recitals Real Property Laws 5(b)(iv)(F) Recommendation 7(x)(iv) Recoverable Costs 4(b)(ii)(C) Returns 3.22(a5(b)(v)(A) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Securities Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a5(b)(xix) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiRecitals Seller Consents 5(a)(iii) Specified Representations 10.2(a)(iiiSeller’s Expense Statement 13 Seller Phase I Real Estate Taxes 7(v) ▇▇▇▇▇ Law 3.12(bSeller Phase II Real Estate Taxes 7(v) Stockholder Set-off Amount 1(a)(x1iv) 775 Agreement 7(ff) 775 Date 7(ff) Shareholder Approval 3.8 Stockholder Meeting 5.8(bDocument 7(x)(i) Straddle Period 1.1 Subsidiary Securities 3.2(bSurveys 9(b)(x)(C) Survival S-X Auditor 7(r)(iii) S-X 2007 Audited Financials 7(r)(iii) TIF Agreement 7(hh) TIF Assignment Date 10.3(a7(hh) Third TIF Determination Date 7(hh) Third-Party Claim 10.4(b11(c)(i) Working Capital Deficit 2.17(fTitle Commitments 9(b)(x)(A) Working Capital Objection Period 2.17(eTitle Company 9(b)(x)(A) Working Capital Objection Statement 2.17(eTitle Policies 9(b)(x)(B) Working Capital Surplus 2.17(fUnpaid Cost to Complete Phase II 4(b)(ii)(E) Unpaid Cost to Complete Phase III 4(b)(ii)(E) Unrecovered Phase II Costs 4(b)(ii)(A) WARN Act 5(b)(ix)(C) Warranty Deed 9(b)(x)(D) West LB 6(b)(v)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gDefined Terms Section Adjustment Amount 2.7(g) Agreement Preamble Amadeus Device Preamble Annual Sales Threshold 2.7(d) Anti-Bribery Laws 3.15(a) Assignment and Assumption Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a2.10(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇Assumed Liabilities 2.3 ▇▇▇▇ Law 3.12(bof Sale 2.10(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bClaim Notice 8.3(a) Straddle Closing 2.9 Closing Date 2.9 Closing Payment 2.5 Commercialization Payment 2.6(a) Commercialization Payment Date 2.6(a) Confidentiality Agreement 5.11(a) ConvaTec Preamble CTI Preamble Deductible 8.5(a) Defaulting Party 2.11 Equipment 2.1(c) Excluded Assets 2.2 Excluded Liabilities 2.4 FDA 3.11 FDCA 3.11(a) Financial Buyer 5.6(d) Included Contracts 2.1(b) Initial Sales Payment Period 1.1 Subsidiary Securities 3.2(b2.7(a) Survival Initial Sales Percentage Amount 2.7(a) Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.7(f) Insurance Policy 5.8 Inventory 2.1(a) Large Acquisition 5.6(c) Non-Financial Buyer 5.6(d) Non-SMM Product Sales 2.7(a) Parent Preamble Patent Assignment 2.10(a) Payment Date 10.3(a2.14(a) Defined Terms Section Percentage Payments Determination Report 2.7(e) Percentage Payments Period 2.7(c) Permitted Acquisition 5.6(c) PPDR 2.7(e) Project Preamble Project Information 5.11(b) Purchase of a Restricted Business 5.6(c) Purchase Price 2.5 Purchased Assets 2.1 Purchased Intellectual Property 2.1(d) Purchaser Preamble Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 8.1 Purchaser Information 5.4(e) Restricted Period 5.6(a) Relevant Acquisition 5.6(c) Sales Payment Period 2.7(c) Sales Percentage Amount 2.7(c) Seller Preamble Seller Disclosure Schedule Article 3 Seller Facility 2.12 Seller Indemnified Parties 8.2 Seller Information 5.4(d) Seller Marks 5.4(a) Seller Sale 5.6(d) Sellers Preamble SMM Platform Preamble SMM Product Sales 2.7(a) Software Assignment 2.10(a) Successor 5.9 Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Transfer Taxes 5.15
Appears in 1 contract
Sources: Asset Sale and Purchase Agreement
Additional Defined Terms. The following terms shall have the meanings set forth on ascribed to them in the pages of this Agreement indicated applicable sections referenced below: 280G Approval 6.3(c) 280G Payments 6.3(c) . Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Amount 2.1 Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aArbitration Demand 8.7(b) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 1.3 Closing 2.4 1.2 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) 1.2 Common Stock Recitals Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eContracts 3.12(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aRegulatory Agency 3.28(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 Recitals D&O Cap 6.4(b) Delivered Tax Returns 3.22(aIndemnified Parties 5.5(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a1.1 Dispute Notice 8.7(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f1.3 Enforceability Exceptions 3.2(b) Escrow Agent 2.16 Period 7.5(d) FCPA 3.25 FDA 3.28(a) Financial Statements 3.7 Fully-Diluted Shares Recitals Indebtedness Pay-off Amount 2.1 Indemnification Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aTermination Date 2.3(a)(ii) Indemnified D&Os 6.4(aParty 7.3(a) Indemnified Indemnifying Party 7.3(a) Insured Parties 10.1(a5.5(b) Interim Major Customers 3.23(a) Major Suppliers 3.23(a) Merger Recitals Merger Consideration 2.1 Merger Sub Preamble Most Recent Balance Sheet 3.9(b3.7 Option Holder Recitals Option Merger Consideration Payable at Closing 2.1(f) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Outstanding Shares Recitals Parent Preamble Parent Closing Balance Sheet 2.17(cBasket 7.4(a) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cDe Minimis Threshold 7.4(a) Parent Working Capital Statement 2.17(cIndemnified Parties 7.1(a) Paying Agent 2.11(aParent Losses 7.1(b) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) PreParties Preamble Party Preamble Per-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Option Merger Agreement Preamble Related Agreements Consideration 2.1 Per-Share Merger Consideration 2.1 Preferred Stock Recitals Real Estate Leases 3.5(a) Seller Group 11.19 Series D Stock 1.1 Release Agreement 2.3(b) Share Merger Consideration Payable at Closing 2.1(e) Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(bFinancial Statements 6.5 Stockholder Recitals Stockholder Indemnified Parties 7.2(a) Stockholder Approval 3.8 Losses 7.2(b) Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Notice 5.4 Stockholder Representative Preamble Surviving Company 1.1
Appears in 1 contract
Additional Defined Terms. The In addition to the terms defined in Section 1.1, each of the following terms shall have is defined in the meanings Section set forth on the pages of this Agreement indicated belowopposite such term: 280G Approval 6.3(c) 280G Payments 6.3(c) Term Section Acquisition Proposal 5.11 Acquisition Sub Companies Preamble Agreed Claims 10.4(g) Agreement Preamble Agreement Date Alternative Transaction 7.5(c) Amended and Restated Community Loan 8.1(j)(i) Annual ERC Financials 5.6(a)(i) Annual ERC Sub Financials 5.6(b)(i)
(i) Annual NSC-Supported NFP Financials 5.6(c)(i) Annual Standalone NFP Financials 5.6(b)(iii)
(e) Ashburn Owner Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aAshburn Retained Cash 2.1(e) Audited Balance Sheet 3.9(bAssumed Kansas Liabilities 2.3(a)(ii) Audited Balance Sheet Date 3.9(bAssumed Liabilities 2.3 Assumed Management Liabilities 2.3(a)(ii) Audited Financial Statements 3.9(bAssumed Subsidiary Liabilities 2.3(a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Bankruptcy Case Recitals Bankruptcy Code Recitals Bankruptcy Court Recitals
(a) Business Recitals Cash Collateral 2.1(c)(iii)(C) Claim Notice 10.3 Closing 2.4 4.1 Closing Date 2.4 4.1 Closing Working Capital Estimate 2.17(aCash Payment 3.2(b)(iv) Company Closing Date Cash Amount 3.2(b)(i) Commitment Fee 3.1
(f) Concord Owner Preamble Company Board Approval 3.5 Company Certificate 2.10(eConcord Retained Cash 2.1(f) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aConfidential Information 7.11 Construction Assets 2.1(l) Company Preferred Stock 2.10(bConsulting and License Agreement 8.1(q)(ii) Company Representative 5.11 Company Software 3.18(lControlled Real Property 5.16(d) Company Third Party Consents 6.3(bCovered Property and Operations 5.17(a)(i) Company Warrant 2.14(aCredit Facilities 5.15(a)(v)
(g) Company Warrant Documents 2.12(aDallas Owner Preamble Dallas Retained Cash 2.1(g) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(bDetermination Letter 5.11(a)(iii) Delivered Tax Returns 3.22(aDevCo Preamble Development Contracts 5.15(a)(iv) DGCL Preamble DIP Financing 7.2(b)(i) Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h7.1 Distributable Cash on Hand 3.2(b)(iii)(B) Employee Plan 3.15(hPlans 5.20(a) Employee Welfare Benefit Plan 3.15(hERC Preamble ERC Assets 2.1(c)(iii) Environmental Approvals 3.21(eERC ▇▇▇▇ of Sale 4.2(a)(i)(G) Environmental Reports 3.21(fERC Conveyance Documents 4.2(a)(i)(G) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiERC Subs 5.1(b) ▇▇▇▇▇▇▇▇ Law 3.12(bAgreements 5.2 ▇▇▇▇▇▇▇▇ Construction Preamble ▇▇▇▇▇▇▇▇ Disclosure Schedule Preamble to Article V ▇▇▇▇▇▇▇▇ Financials 5.6(b)(iv) Stockholder Approval 3.8 Stockholder Meeting 5.8(b▇▇▇▇▇▇▇▇ Indemnitees 10.2 ▇▇▇▇▇▇▇▇ Losses 10.2 ▇▇▇▇▇▇▇▇ Parties Preamble ERISA Affiliate 5.20(a) Straddle Period 1.1 Subsidiary Securities 3.2(bExcluded Assets 2.2 Excluded Contracts 2.2(d) Survival Excluded Liabilities 2.4 Execution Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fPreamble FECA 5.11(f)
Appears in 1 contract
Sources: Master Purchase and Sale Agreement
Additional Defined Terms. The As used herein, the following terms shall have the meanings set forth on defined in the pages of this Agreement recitals or sections indicated below: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Agreement Preamble Assignment and Assumption Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aSection 14.03(d) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Assumed Liabilities Section 18.02 Business Representations Introductory paragraph to Article VIII Business Representations Damages Cap Section 12.09 Closing 2.4 Section 11.01 Closing Conditions Section 10.01 Closing Date 2.4 Section 3.03 Closing Working Capital Estimate 2.17(aStatement Section 11.02(a)(iv) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eRecital A Contracts Section 8.15 Cut-Off Time Section 15.04 Deed Transfers Section 14.03(a) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aDocuments Section 15.01(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(eDue Diligence Materials Section 3.01(f) Environmental Reports 3.21(fSection 8.09 Executive Order Section 1.01, definition of Specially Designated National or Blocked Person Facility Agreements Section 2.02(c) Escrow Agent 2.16 Escrow Facility/Facilities Recital C Facility Owners Recital B Failure of Condition Notice Section 13.02(e) Financials Section 8.01(a) HUD Recital N HUD Loan Assumptions Recital N Improvements Section 2.02(a)(i) Indemnification and Contribution Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aSection 14.04(a) Indemnified D&Os 6.4(aParty Section 12.06(a) Indemnified Parties 10.1(aIndemnifying Party Section 12.06(a) Interim Balance JV Agreement Section 14.01(a) Land Section 2.02(a)(i) Lender Recital G Loan Section 14.04(a) Local Counsel Costs Section 15.01(b) Manager Pooling Agreement Section 14.03(e) New Pool One Facility Owner(s) Recital G New Pool One Facility Tenant(s) Recital H New Facility Owner(s) Recital O New Management Agreement Section 14.03(c) Operating Cash Infusion Section 2.03 Operating Lease Section 14.03(b) Other Refinancing Fees and Expenses Section 16.02 Other Shared Closing Costs Section 15.04 Owned Assets Section 2.02 Personal Property Section 2.02(b)(v) Pool One Closing Section 11.01(a) Pool One Closing Date Section 11.01(a) Pool One Transferor Contribution Recital I Pool Two Closing Section 11.01(b) Pool Two Closing Date Section 11.01(b) Pool Two Transferor Contribution Recital S Property Taxes Section 15.04(a) Prorations Section 15.04 Refinancing Recital F Refinancing Fee Section 16.02 Refinancing Term Sheet 3.9(bRecital F Refinancing Third-Party Costs Section 15.01(b) Interim Balance Sheet Date 3.9(bResidence Agreements Section 2.02(c) Interim Financial Statements 3.9(bRestructuring Recital U Restructuring Documents Section 14.05 Retained Assets Section 2.02 Retained Liabilities Section 18.01 Shared Expenses Section 15.05 Shenandoah Facility Section 18.02 Survey Section 3.02(a) InThird-the-Money Company Option 2.13(aParty Costs Section 15.01(b) In-the-Money Company Warrant 2.14(aTitle Insurance Costs Section 15.02 Transfer Taxes Section 15.03 Transferee Preamble Transferee Pool One Cash Contribution Amount Recital J Transferee Pool One Contribution Recital J Transferee Pool Two Cash Contribution Amount Recital R Transferee Pool Two Contribution Recital R Transferee Default Notice Section 13.02(d) Leased Property 3.14(aTransferee Notice of Objection to Transferor Reimbursable Transaction Costs Section 13.02(e) Letter Amendment Premable Letter Transferee’s Objection Notice Section 13.02(d) Transferor Preamble Transferor Board Consent Section 7.02(a) Transferor Contribution Recital Q Transferor Default Notice Section 13.02(c) Transferor’s Failure of Transmittal 2.12(aCondition Objection Notice Section 13.02(e) License Agreement 3.16(a)(xiTransferor’s Objection Notice Section 13.02(c) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)TRS Recital D
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gPortion 10.3(b) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aApplicable D&O Claim 10.5(e) Audited Applicable Escrow Final [Country] Tax Reimbursement Shortfall 10.3(g)(iii) Applicable Escrow/Setoff Final [Country] Tax Reimbursement Shortfall 10.3(g)(iii) Applicable Excess 10.3(g)(ii) Asserted Losses 10.3(a) Assumed Option 6.11 Assumed Option Exercise Price 6.11 Assumed Option Holder 6.11(a)(i) Assumed Option Spread Value Per Share 6.11(a)(ii) Balance Sheet 3.9(b4.5(a)(i) Audited Balance Sheet Date 3.9(bBlock Trade 3.9(c) Audited Financial Statements 3.9(bCertificate 3.3(a)(i) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Commissioner 4.3 Change in Recommendation 6.9(b) Charter Amendment 6.19 Closing 2.4 2.2 Closing Date 2.4 2.2 Closing Date Net Working Capital Estimate 2.17(aStatement 3.6(c) Closing Disbursement 2.2(c)(ii) COBRA 4.16(c) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eRecommendation 6.9(a) Company Disclosure Schedule 3.0 Article 4 Company Disclosure Schedules 3.0 Indemnified Parties 10.2 Company Option 2.13(aIntellectual Property 4.13(a) Company Preferred Stock 2.10(bMateriality Qualified Provisions 10.1 Company Representatives 6.5(a) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(aSpecified Representations 10.5(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 6.6(a) Contingent Assumed Option 6.11(a)(iii) Contingent Payment Amounts 6.11(b) Contractors 4.17(b) Controlling Party 10.3(e) D&O Cap 6.4(bIndemnified Parties 6.17(a) Delivered Tax Returns 3.22(aDe Minimis Amount 10.5(c) Deposit 9.4(d) DGCL Preamble Disclosure Statement 5.8(a2.1 Disputed Line Items 3.8(b) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a3.5 DOL 4.16(b)
(a) Earn-Out Shares 3.1(c) Earn-Out Statement 3.7(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h2.2(a) Employee Plan 3.15(hEmployment Agreement Preamble End Date 8.1(b) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(fEscrow Account 2.2(c)(i) Escrow Agent 2.16 2.2(c)(i) Escrow Agreement 2.16 2.2(c)(i) Escrow Fund 2.16 Final [Country] Tax Reimbursement 10.3(g)(iii) Escrow Shares 2.2(c)(i) Estimated Working Capital Surplus 2.17(bAmount 10.3(g)(ii)
(a) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Estimated Net Working Capital Statement 2.17(c3.6(a) Paying Exchange Agent 2.11(a2.2(c)(ii) Paying Exchange Agent Agreement 2.11(a2.2(c)(ii) Payment Fund 2.11(aExpense Reimbursement 8.3(a)(ii) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(aSAMPLE Fairness Approval 6.8(b) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fFairness Hearing 6.8(b)
Appears in 1 contract
Sources: Merger Agreement
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAccounting Firm 3.4(b) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Adjustment Event 3.6 Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aApplicable Fund GAAP 5.20(e) Audited Balance Sheet 3.9(bBarrack Privilege Parties 2.1(b)(vi) Audited Balance Sheet Date 3.9(bBasket 10.4(a) Audited Financial Statements 3.9(bBenchmark Cumulative FFO 3.5(a)(i) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(aBusiness Intellectual Property 5.16(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) CAH License Agreement 3.16(a)(xi4.2(a)(iv) License Agreements 3.16(a)(xiCap 10.4(a) Majority Effective Time Holders 9.1(cCC Preamble CC Adviser 5.21(a) Measurement Date 1.1 Merger CC Assumed Liabilities 2.1(c) CC Consolidated Entities 5.12(a) CC Contributed Assets 2.1(a) CC Contribution Closing 2.1(a) CC Disclosure Letter 5 CC Holdings Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) CC Pre-Closing Contribution 2.1(a) CC Retained Assets 2.1(b) CC Retained Liabilities 2.1(d) CC Transferred Books and Records 2.1(a)(iv) CCH Preamble CFI Preamble CFI Assumed Liabilities 2.2(c) CFI Board Recitals CFI Contributed Assets 2.2(a) CFI Contribution Closing 2.2(a) CFI Credit Agreement 2.2(c) CFI Disclosure Letter 6 CFI GP Investments 3.5(a)(iii) CFI Indemnified Parties 10.3 CFI Pre-Closing Contribution 2.2(a) CFI Privilege Parties 2.1(b)(vi) CFI Retained Assets 2.2(b) CFI Retained Liabilities 2.2(d) CFI Stockholders Meeting 7.8(b) Change of Recommendation 7.9(a) Claim 10.5(a) Closing 4.1 Closing Date 4.1 Colony ▇▇▇▇ Transfer Agreement Recitals Consideration 3.1 Contingent Consideration 3.1 Contingent Consideration Account 3.5(b) Contingent Consideration Dispute Period 6.1 Preliminary 3.5(f) Contingent Consideration Statement 3.5(e)(iii) Contingent Consideration Statements 3.5(e)(iii) Contribution 3.1 Contributor Preamble Contributor Indemnified Parties 10.2 Contributors Preamble CRM Recitals CRM CRP Interests Recitals CRM Interests Recitals CRM Investment Management Agreement 4.2(a)(ii) CRP Recitals CRP Interests Recitals D&O Tail 7.11(b) Disbursement Schedule 3.2(a)(i) Dispute Notice 3.4(b) Estimated CC Closing Balance Sheet 2.17(aAdjustment 3.2(a)(ii) Preliminary Estimated CC Closing Cash Consideration 3.2(a)(ii) Estimated CC Closing Date Cash 3.2(a)(ii) Estimated CC Closing Share Consideration 3.2(a)(ii) Estimated CC Closing Unit Consideration 3.2(a)(ii) Estimated CC Closing Unpaid Indebtedness 3.2(a)(ii) Estimated CC Working Capital 3.2(a)(ii) Estimated CCH Closing Unit Consideration 3.2(a)(ii) Estimated CFI Common Stock Count 3.2(a)(ii) Estimated CFI Series A Preferred Stock Count 3.2(a)(ii) Estimated CFI Series B Preferred Stock Count 3.2(a)(ii) Estimated Closing Consideration 3.2(a)(ii) Estimated Closing Statement 2.17(a3.2(a)(ii) Prior Merger Estimated CRP Closing Adjustment 3.2(a)(ii) Estimated CRP Closing Date Cash 3.2(a)(ii) Estimated CRP Closing Unpaid Indebtedness 3.2(a)(ii) Estimated CRP Working Capital 3.2(a)(ii) Estimated FHB Closing Cash Consideration 3.2(a)(ii) Estimated FHB Closing Unit Consideration 3.2(a)(ii) Estimated ▇▇▇▇▇▇▇▇ Closing Cash Consideration 3.2(a)(ii) Estimated ▇▇▇▇▇▇▇▇ Closing Unit Consideration 3.2(a)(ii) FFO Additional Contingent Consideration Amount 3.5(a)(iv) FFO Additional Contingent Payment Units 3.5(a)(v) FFO Contingent Consideration Amount 3.5(a)(vi) FFO Contingent Consideration Statement 3.5(e)(ii) FFO Contingent Payment Units 3.5(a)(vii) FFO Lower Threshold 3.5(a)(viii) FFO Measurement Period 3.5(a)(x) FFO Target 3.5(a)(x) FHB Preamble Final CC Closing Adjustment 3.4(b) Final CC Closing Cash Consideration 3.4(b) Final CC Closing Date Cash 3.4(b) Final CC Closing Share Consideration 3.4(b) Final CC Closing Unit Consideration 3.4(b) Final CC Closing Unpaid Indebtedness 3.4(b) Final CC Working Capital 3.4(b) Final CCH Closing Unit Consideration 3.4(b) Final Closing CFI Common Stock Count 3.4(b) Final Closing Consideration 3.4(b) Final Closing Series A Preferred Stock Count 3.4(b) Final Closing Series B Preferred Stock Count 3.4(b) Final Closing Statement 3.4(b) Final CRP Closing Adjustment 3.4(b) Final CRP Closing Date Cash 3.4(b) Final CRP Closing Unpaid Indebtedness 3.4(b) Final CRP Working Capital 3.4(b) Final FHB Closing Cash Consideration 3.4(b) Final FHB Closing Unit Consideration 3.4(b) Final ▇▇▇▇▇▇▇▇ Closing Cash Consideration 3.4(b) Final ▇▇▇▇▇▇▇▇ Closing Unit Consideration 3.4(b) Financial Statements 5.12(a) Fund Financial Statement 5.20(e) Government Entity 5.22(b) Independent Directors 3.5(e)(i) Interests 6.5(c) Leased Real Property 5.17(a) Material Contracts 5.14(a) New Shares 3.3(b)(ii) New Units 3.3(b)(i) NewCo Preamble NewCo Interests Recitals Non-RE Capital Raise Contingent Consideration Statement 3.5(e)(iii) Non-RE Capital Raise Contingent Payment Units 3.5(c)(iii) Non-RE Capital Raise Target 3.5(a)(xi) Non-RE Cumulative Capital Raise 3.5(a)(xiii) Notice of Disagreement 3.5(f) OP Preamble OP LLC Agreement Preamble Related Agreements 3.5(a4.2(a)(v) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiPayment Due Date 10.6(f) Specified Representations 10.2(a)(iiiPer Claim Threshold 10.4(a) Personal Information 5.23 Post-Closing Statement 3.4(a) Privacy Policy 5.23 Proxy Statement 7.8(a) Qualified Third-Party Capital 3.5(a)(xiv) RE Capital Raise Additional Contingent Consideration Amount 3.5(a)(xv) RE Capital Raise Additional Contingent Payment Units 3.5(a)(xvi) RE Capital Raise Contingent Consideration Amount 3.5(a)(xvii) RE Capital Raise Contingent Consideration Statement 3.5(e)(i) RE Capital Raise Contingent Payment Units 3.5(a)(xviii) RE Capital Raise Lower Threshold 3.5(a)(xix) RE Capital Raise Measurement Period 3.5(a)(xx) RE Capital Raise Target 3.5(a)(xxi) RE Cumulative Capital Raise 3.5(a)(xxii) Real Property Leases 5.17(a) Recommendation 6.2(b) REIT 6.8 Requisite CFI Stockholder Approvals 6.2(a) Requisite Charter Amendment Stockholder Approvals 6.2(a) Requisite Issuance Stockholder Approvals 6.2(a) Review Period 3.4(b) Routine Examination 5.9(a) ▇▇▇▇▇▇▇▇ Law 3.12(bPreamble Share Retention Notice 7.21(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(bShared Communications 2.1(b)(vi) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Special Committee Recitals Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f10.6(a)
Appears in 1 contract
Sources: Contribution and Implementation Agreement (Colony Financial, Inc.)
Additional Defined Terms. The Each of the following terms shall have is defined in the meanings Section set forth on the pages of this Agreement indicated belowopposite such term: 280G Approval 6.3(c2018 Interim Financial Statements Section 5.13 Adjustment Escrow Account Section 2.8(a)(iii) 280G Payments 6.3(cAdjustment Escrow Amount Section 2.8(a)(iii) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdviser Subsidiary Section 3.19(d) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aBD Sub Amendment Section 5.8(a) Audited Balance Sheet 3.9(bBD Sub Withdrawal and Liquidation Section 5.8(a) Audited Balance Sheet Date 3.9(bBD Subsidiary Section 5.8(a) Audited Financial Statements 3.9(bCalculated Payout Section 2.15(c)(ii) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Section 2.2 Charter Documents Section 3.1(c) Closing 2.4 Section 2.13 Closing Date 2.4 Section 2.13 Closing Working Capital Estimate 2.17(aStatement Section 2.14(b) Closing Stockholder Payment Section 2.8(a)(vi) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Basic Representations Section 8.1 Company Disclosure Schedule 3.0 Article III Company Disclosure Schedules 3.0 Fundamental Representations Section 8.1 Company Option 2.13(aIndemnitees Section 5.5 Company Intellectual Property Section 3.13(a) Company Preferred Stock 2.10(bRevenue Section 2.15(c)(viii) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(bSection 3.4(b) Delivered Tax Returns 3.22(aDe Minimis Amount Section 8.3(a) Deductible Section 8.3(a) DGCL Preamble Disclosure Statement 5.8(aRecitals Disputed Amounts Section 2.14(e)(iii) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aSection 2.11 Earn-Out Payment Date Section 2.15(c)(iii) Earn-Out Payments Section 2.15(c)(ii) Earn-Out Periods Section 2.15(c)(i) Earn-Out Start Date Section 2.15(c)(i) Effective Time 2.4 Employee Pension Benefit Plan 3.15(hSection 2.2 End Dates Section 2.15(c)(i) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(fERISA Client Section 3.21(c) Escrow Agent 2.16 Section 2.8(a)(iii) Escrow Agreement 2.16 Escrow Fund 2.16 Section 2.8(a)(iii) Estimated Cash Definition of “Estimated Closing Statement” Estimated Closing Date Indebtedness Definition of “Estimated Closing Statement” Estimated Closing Working Capital Surplus 2.17(b) FDA Requirements 3.19(aDefinition of “Estimated Closing Statement” Estimated Seller Expenses Definition of “Estimated Closing Statement” Expense Fund Section 2.8(a)(iv) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Settlement Section 8.5 Financial Statements 3.9(bSection 3.5 First Earn-Out Payment Section 2.15(c)(ii) InFirst Earn-the-Money Company Option 2.13(aOut Period Section 2.15(c)(i) In-the-Money Company Warrant 2.14(aFirst End Date Section 2.15(c)(i) Leased Property 3.14(aFirst Period Growth Rate Section 2.15(c)(iv) Letter Amendment Premable Letter of Transmittal 2.12(aGeneral Indemnity Cap Section 8.3(b)(i) License Agreement 3.16(a)(xiGeneral Survival Expiration Date Section 8.1 Independent Accountants Section 2.14(e)(iii) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Information Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Section 5.7
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement and the Transaction Documents, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Algeria Cash Consideration 2.4 Asset Transfer Agreements 2.3 Balance Sheet 3.9(b3.6(a)(ii) Audited Balance Sheet Date 3.9(b3.6(a)(ii) Audited Financial Statements 3.9(bBankruptcy and Equity Exception 3.2(a) California Stockholder Approval 3.8 Certificate of Merger Business Intellectual Property 3.10 Business Leased Real Property 3.9(a) Cash Consideration 2.4 Claims 10.4 CLIA 1.1 Claim Notice 8.3(a) Closing 2.4 2.7(a) 428928/HOUDMS Closing Date 2.4 2.7(a) Closing Working Capital Estimate 2.17(aTime 2.7(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eControlling Party 8.3(d) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aDeductible 8.5(a) Company Preferred Stock 2.10(bDeposit 2.4(a) Company Representative 5.11 Company Software 3.18(lDispute Notice 2.5(b) Company Third Party Consents 6.3(bDispute Representatives 11.11(a) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(fEmployees List 3.13(a) Escrow Agent 2.16 2.4(a) Escrow Agreement 2.16 Escrow Fund 2.16 Estimated 2.4(a) Excluded Liabilities 2.2 Final Allocation 2.6 Final Closing Net Cash 2.5(c) Final Closing Net Working Capital Surplus 2.17(b2.5(c) FDA Requirements 3.19(aFinancial Statements 3.6(a) Final Financing Commitments 4.7 ICC 11.11(b) Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.5(c) Independent Contractors List 3.13(a) Initial Closing 2.7(b) Initial Closing Date 2.7(b) Initial End Date 7.1(f) KOC 5.16 Kuwait Cash Consideration 2.4 Net Working Capital 2.17(eand Net Cash Calculation 2.5(a) Firm 11.9 FTC 6.2(aNon-controlling Party 8.3(d) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Party Preamble PD Cyprus/Joint Venture Indemnified D&Os 6.4(a) Party Section 5.8 Purchase Price 2.4 Purchaser Preamble Purchaser Disclosure Schedule Article 4 Purchaser Indemnified Parties 10.1(a8.1 Recipient 9.3(a) Interim Balance Sheet 3.9(bRelevant Amount Section 5.11 Restructuring 5.15 Restructuring Plan 5.15 Rig Capital Expenditure Program 5.2(b) Interim Balance Sheet Rules 11.11(b) Seller Preamble Seller Disclosure Schedule Article 3 Seller Guarantees Section 5.11 Seller Indemnified Parties 8.2 Subsequent Closing 2.7(b) Subsequent Closing Date 3.9(b2.7(b) Interim Financial Statements 3.9(bSubsequent End Date 7.1(i) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Target Net Working Capital Determination 2.17(cAmount 2.5(d) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(aTeam Source 3.13(a) Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Transfer Agreements 2.3 428928/HOUDMS
Appears in 1 contract
Sources: Sale and Purchase Agreement (Weatherford International PLC)
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAbandonment Notice 2.7(b)(v) 280G Accounting Firm 2.9(c) Acquired Business 5.15(a)(ii) Acquired Competing Business 5.15(a)(ii) Acquired Contracts Exhibit B Adjusted Net Transfer Amount 7.3(a)(ii) Agreed Assumptions 1.1 Assigned Intellectual Property Exhibit B Alternate Transaction 5.14 AndroGel Milestone Payments 6.3(c2.6(a) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAndroGel Net Sales Records 2.6(d) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aArbitral Tribunal Schedule 12.10 Arbitration Schedule 12.10 Assets 7.2(e)
(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Non-Consolidated Financial Statements 3.9(b3.6(c) California Stockholder Approval 3.8 Certificate Business Intellectual Property 3.13(a) Buyer Parent Preamble Buyer Parent Field of Merger 2.4 Claims 10.4 CLIA 1.1 Use 2.12(a) Buyers Preamble Buyers Indemnified Parties 11.1(a) Buyers Benefit Plan 7.9(a) Buyers Dedicated Employees 5.11(b) Buyers Non-Business Pension Indemnification Amount 7.2(f) Buyers Pension Indemnification Amount 7.2(e)
(a) Buyer’s U.K Pension Plan 7.4(a) Cap 11.1(b)(i) Certain Nations 3.21(c) Change of Control Payments 3.17(f) Closing 2.4 2.7(a) Closing Date 2.4 2.7(a) Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Net Working Capital Statement 2.17(c2.9(a) Paying Agent 2.11(aCommercially Reasonable Efforts 2.6(c) Paying Agent Agreement 2.11(aCommonly Controlled Entity 3.18(a) Payment Fund 2.11(aCompeting Business 5.15(a) Pre-Competition Law Filings 5.3(b) Confidential Information 12.3 Days 1.3 DC Transfer Amount 7.5(b) DC Employees 7.5(a) Deductible 11.1(b)(i) Deferred Local Business 2.7(b)(i)(A)(1) Deferred Local Closing Period 6.1 Preliminary 2.7(b)(ii) Deminimis Amount 11.1(b)(i) Dollars 1.3 Employee Procedures 5.11(a) Environmental Remediation Costs 11.1(b)(iv) Estimated Net Cash 2.5(c) European Bank Facility 5.6(a) Euros 1.3 Fair Market Value 7.2(e) Final Determination Date 7.3(a) Final Statement of Closing Balance Sheet 2.17(aNet Working Capital 2.9(d) Preliminary Closing Final Statement 2.17(aof Net Cash 2.9(e) Prior Merger Agreement Preamble Related Agreements 3.5(aFinal Transfer Amount 7.3(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiFirst Pension Transfer Amount 7.3(a) ▇▇▇▇▇▇▇▇ Law 3.12(b5.21(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bGovernment Officials 3.21(a)(i) ICC Rules Schedule 12.10 India Mandatory Takeover Offer 5.20 Initial Purchase Price 2.5(a) Insurance Proceedings 5.17(d) Intercompany Loans 5.5(a) ▇▇▇▇▇▇▇▇ Indemnification 11.1(a)(iv) ▇▇▇▇▇▇▇▇ Release 5.29 Licensed Patents 3.13(a)(ii) Material Contracts 3.14(a) Milestone Due Date 2.6(b) Milestone Report 2.6(b) Mixed Account 5.19(b)
(a) Net Cash Statement 2.9(a) Net Transfer Amount 7.3(a)(i) Non-Business Pension Liabilities 7.2(f) Non-Business Transferred Amounts 7.2(f) Non-Final Injunction 2.7(b)(i)(B)(1) Non-Pharma Loans 5.5(a) Non-U.S. Business Employee 7.1 Non-U.S. Buyer DC Plans 7.5(a) Non-U.S. Buyer Pension Plans 7.4(a) Non-U.S. Former Employee 1.1 Non-U.S. Seller DC Plans 7.5(a) Non-U.S. Transferred Employee 7.1 Objection 2.9(b) Owned Patents 3.13(a)(i) Party or Parties Preamble Pension Plan Employees 7.4(a) Pension Plan Former Employees 7.4(a) Pension Transfer Amounts 7.3(a) and 7.4(b) Pharma Health Field of Use 2.12(a) Post-Closing Straddle Period 1.1 Subsidiary Securities 3.2(b11.10(c) Survival Pre-Closing Straddle Period 11.10(a) Purchase Price 2.5(a) Related Party Contracts 3.19(a) Registered Trademarks 3.13(a)(iii) Response 2.9(c) Restricted Period 5.15(a) Section 75 Debt 7.4(h) Seller Non-U.S. Benefit Plans 3.18(a) Seller U.S. Benefit Plans 3.18(c) Seller Parent Preamble Seller Parent Share of AndroGel Litigation Costs 2.6(e) Seller Parent Representations Article 3 Seller Pension Plans 7.4(a) Sellers Preamble Sellers Dedicated Employees 5.11(b) Sellers Indemnified Parties 11.2(a) Sellers Non-Business Pension Indemnification Amount 7.2(f) Sellers Pension Indemnification Amount 7.2(e) Shares Recitals SIP 7.2(g) Sodufa Recitals Sodufa Shares Recitals Sold Company Pension Plan 7.4(a) Solvay Pharmaceuticals Belgium Recitals Solvay Pharmaceuticals Belgium Employees 7.1 Special Indemnification Matters 11.1(a)(iii) SPML Recitals SPML Shares Recitals Straddle Period 6.2 Takeover Documents 5.20 Tax Claim 11.11(a) Terlin Recitals Termination Date 10.3(a10.1(b) Transferred U.S. Plans 3.18(d) Thai Business Restructuring 2.1(c) Third Party Claim 10.4(b11.3(b) Working Capital Deficit 2.17(fThird Party Financial Indebtedness 5.6(a) Working Capital Objection Period 2.17(eTrailing Benefit Payments 7.3(a)(iii) Working Capital Objection Statement 2.17(eTransfer Credits 7.4(a) Working Capital Surplus 2.17(fTransferred Employee 7.1 Transferred Amounts 7.2(e) Transition Services Agreement 5.16 Unconsolidated Sold Companies 3.6(c) Unaudited Financial Statements 3.6(a) U.S Business Employee 7.1 U.S. Buyer DC Plans 7.3(b) U.S. Former Employee 1.1 U.S. Transferred Employee 7.1 Voluntary Guidance 3.21(a)(ii) WARN Act 3.17(e)
Appears in 1 contract
Sources: Stock and Asset Purchase Agreement (Abbott Laboratories)
Additional Defined Terms. The For purposes of this Agreement and the Ancillary Agreements, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cAccounts Receivable 2.1(b)(ii) 280G Payments 6.3(cAccrued Payroll and Benefits 2.4(e) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAcquired Company Intellectual Property 3.10 Acquired Company Leased Real Property 3.9(b) Acquired Company Real Property 3.9(a) Adjustment Calculation 2.6(a) Adjustment Notice 2.6(a) Affiliate Indemnified Party 5.12 Agreement Preamble Approval Notification 11.4(f) Approval Order Approval Order 5.3(a) Artek Preamble Assignment and Assumption Agreement 2.9(a)(ii) Assumed Liabilities 2.3 Aterian Preamble Bankruptcy Avoidance Actions 2.2(m) Bidding Procedures Order 5.3(a) Bill of Sale 2.9(a)(i) Bonus Payments 10.1(e) Business Information 5.9(b) Business Intellectual Property Rights 3.10 Calculation Principles 2.6(a) Chosen Court 12.13 Ciba Environmental Indemnity Assignment 2.9(a)(xiii) Claim Notice 8.3(a) Closing 2.8 Closing Allocation Schedule 2.7 Closing Date Preamble 2.8 Commitment Letters 4.7 Confidentiality Agreement 5.9(a) Continuation Period 10.1(c) Controlling Party 8.3(d) Control Notice 11.4(b) Deposit Agent 2.5(b)(i) Deposit Amount 2.5(b)(i) Dispute Notice 2.6(c)(ii) Environmental Authorizations 3.15(a) European Trade Accounts Payable 2.4(c) Excluded Assets 2.2 Excluded Intellectual Property 2.2(h) Excluded Liabilities 2.4 Final Cash Consideration 2.5(a) Final Closing Net Working Capital 2.6(a) Financial Statements 3.5 German GAAP Financial Statements 5.22(b) Governmental Antitrust Authority 5.5(a) Initial Allocation Certificate 6.8 Antitrust Filings 6.2(aSchedule 2.7 Included Contracts 2.1(b)(iii) Audited Balance Sheet Income Statement 3.5 Indemnified Party 8.3(a) Indemnifying Party 8.3(a) Independent Accounting Firm 2.6(f) Independent Consultant 11.4(g) Initial Allocation Schedule 2.7 Initial Cash Consideration 2.5(a) Inventory 2.1(b)(i) Inventory Cap 2.6(b) IP Assignments 2.9(a)(v) IP License Agreement 2.9(a)(v) Isopetronate HL-44 Toll Manufacturing Agreement 5.21 Latin American Purchased Assets 2.10(d) Lease 3.9(b) Audited Balance Sheet Date 3.9(bLoss Compensation Claim 5.22(b) Audited Financial Statements 3.9(bMarked Assets 5.15(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(aMaterial Contracts 3.11(a) Company New Defined Benefit Plan 10.2(a) Non-Controlling Party 8.3(d) Off-Site Liabilities 2.4(k) Other Purchased Assets 2.10(a) Owned Real Property 2.1(b)(v) Pension Plan 10.2(a) Plan Assets Amount 10.2(b) Profit Transfer Claim 2009 5.22(b) Purchase Price 2.5(a) Purchased Assets 2.1(b) Purchased Intellectual Property 2.1(b)(vi) Purchaser Preamble Company Board Approval 3.5 Company Certificate 2.10(ePurchaser Indemnified Parties 8.1 Regulation 3.22 Sale Motion 5.3(a) Company Savings Plan 10.3(a) Seller Preamble Seller Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Article 3 Seller Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a8.2 Seller Information 5.15(f) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiMarks 5.15(a) Specified Representations 10.2(a)(iiiSeptember ’09 Net Assets Statement 3.5 Share Transfer Agreement 2.9(a)(iii) ▇▇▇▇▇ Law 3.12(bShared Accounts Payable 2.4(d) Stockholder Approval 3.8 Stockholder Meeting 5.8(bTBT Supply Agreement 2.9(a)(x) Straddle Period 1.1 Subsidiary Securities 3.2(bTOT Supply Agreement 2.9(a)(xi) Survival Date 10.3(aTNPP Supply Agreement 5.21(a) TPP/LPE Supply Agreement 2.9(a)(xii) Third Party Claim 10.4(b8.3(b) Working Capital Deficit 2.17(fThreshold 8.5(a)(ii) Working Capital Objection Period 2.17(eTrade Accounts Payable 2.4(b) Working Capital Objection Statement 2.17(eTransferred Employee 10.1(b) Working Capital Surplus 2.17(f)Transfer Taxes 9.1(e) Transferred Employee 10.1(b) Transition Services Agreement 2.9(a)(ix) Welfare Plan 10.4 Weston 705 Supply Agreement 5.21
Appears in 1 contract
Sources: Share and Asset Purchase Agreement
Additional Defined Terms. The In addition, for the purpose of this Agreement, the following terms shall have the following meanings set forth on in the pages of this Agreement indicated belowSections indicated: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gProcedures 6.1(a) Agreement Preamble Agreement Date Preamble APIs See definition of SpinCo Business, 1.1 Authorized Representative 7.2 Bankruptcy Code 8.5(h) Base Proceeds 3.4(e) Bulk Request 6.1(b) Cash Allocation Certificate 6.8 Antitrust Filings 6.2(a3.4(f)(ii) Audited Balance Sheet 3.9(bCEO Negotiation Request 7.3 Chosen Courts 10.2(b) Audited Balance Sheet Date 3.9(bCommingled Excluded Information 6.11 Contribution Recitals control See definition of Affiliate, 1.1 controlled by See definition of Affiliate, 1.1 Covered Parent Patent 8.4 Covered SpinCo Patent 8.4 CPR 7.4 Delayed Parent Asset 2.4(h) Audited Financial Statements 3.9(bDelayed Parent Liability 2.4(h) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(aDelayed SpinCo Asset 2.4(c) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eDelayed SpinCo Liability 2.4(c) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aDispute 7.1 e-mail 10.5 Encumbrances 3.4(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(aEndo Recitals Excess Proceeds 3.4(f) Final Working Capital 2.17(eStock Allocation 3.4(k)(i) Firm 11.9 FTC 6.2(aIndemnifying Party 4.4(a) Fundamental Representations 10.2(a)(iiIndemnitee 4.4(a) HSR Act 6.2(aIndemnity Payment 4.4(a) Indemnified D&Os 6.4(aInitial Cash Allocation 3.4(e)(ii) Indemnified Parties 10.1(aInitial Notice 7.1 Initial SpinCo Allocation 3.4(e)(i) Institutional Accredited Investor See definition of Qualified Shareholder, 1.1 Interim Excess Determination 3.4(l) Interim Balance Sheet 3.9(bExcess Proceeds 3.4(l) Interim Balance Sheet Date 3.9(bInternet Properties See definition of Intellectual Property Rights, 1.1 Licensees 8.5(d) Interim Financial Statements 3.9(bLicensors 8.5(d) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Mediation Request 7.4 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Recitals Merger Sub Recitals Officer Negotiation Request 7.2 Parent Preamble Parent Closing Balance Sheet 2.17(cAccounts 2.9(a) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cAssets 2.2(b) Parent Working Capital Statement 2.17(cBoard Recitals Parent Books and Records 2.2(a)(xiii) Paying Agent 2.11(aParent Indemnitees 4.2 Parent Liabilities 2.3(b) Paying Agent Agreement 2.11(aParent SpinCo Share 3.4(h) Payment Fund 2.11(aParent Transferred Entity/Subsidiary Liability 2.1(a) Patents See definition of Intellectual Property Rights, 1.1 Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(aRedemption Notification Deadline 3.4(g) Preliminary Closing Statement 2.17(aProcedure 7.4 Prohibited Business 8.3(c) Prior Merger Agreement Preamble Related Agreements 3.5(aQualified Institutional Buyer See definition of Qualified Shareholder, 1.1 Redemption 3.4(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiRedemption Consideration 3.4(c) Removed Party 2.7(b) Separation Recitals Separation Step Plan 2.1(a) Specified Representations 10.2(a)(iiiAncillary Agreement 10.18(b) ▇▇▇▇▇ Law 3.12(bSpinCo Preamble SpinCo Accounts 2.9(a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bSpinCo Allocation 3.4(f)(i) Straddle Period SpinCo Assets 2.2(a) SpinCo Financing Arrangements 2.12 SpinCo Indemnitees 4.3 SpinCo Liabilities 2.3(a) SpinCo Real Property Leases See definition of SpinCo Real Property, 1.1 SpinCo Retained Cash Amount 2.2(b)(ix) SpinCo Transferred Entity/Subsidiary Securities 3.2(bLiability 2.1(a) Survival Date 10.3(a) Third Third-Party Claim 10.4(b4.5(a) Working Capital Deficit 2.17(fTrade Secrets See definition of Intellectual Property Rights, 1.1 Trademarks See definition of Intellectual Property Rights, 1.1 Transfer Documents 2.1(c) Working Capital Objection Period 2.17(eTransition Committee 2.13 under common control with See definition of Affiliate, 1.1 Unreleased Parent Liability 2.5(b)(ii) Working Capital Objection Statement 2.17(eUnreleased SpinCo Liability 2.5(a)(ii) Working Capital Surplus 2.17(fValuation Advice 3.2(b)
Appears in 1 contract
Additional Defined Terms. The As used herein, the following terms shall have the meanings set forth on defined in the pages of this Agreement recitals or sections indicated below: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAccess Indemnified Parties Section 3.01(b) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Business Representations Introductory paragraph to Article VIII Closing 2.4 Section 11.01 Closing Date 2.4 Section 3.03 Closing Working Capital Estimate 2.17(aStatement Section 11.02(a)(v) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(eContracts Section 8.17 Due Diligence Materials Section 3.01(f) Environmental Reports 3.21(fSection 8.09 Existing Venture Agreement Recital B Facility Agreements Section 2.02(c) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(bFacility/Facilities Recital D Facility Owners Recital F Failure of Condition Notice Section 13.02(f) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(aGP Facility Owner Interests Recital G GP Interest Recital E Improvements Section 2.02(a)(i) Indemnified D&Os 6.4(aParty Section 12.11(a) Indemnified Parties 10.1(aIndemnifying Party Section 12.11(a) Interim Balance Sheet 3.9(bLand Section 2.02(a)(i) Interim Balance Sheet Date 3.9(bManager Recital I MetLife Recital B MetLife Consent Section 9.08 MetLife Letter Agreement Section 9.08 Mutual Release Section 9.08 New Investor Preamble New Investor Default Notice Section 13.02(e) Interim Financial Statements 3.9(bNew Investor’s Objection Notice Section 13.02(e) InOwned Assets Section 2.02 Personal Property Section 2.02(b)(v) Pool One GP Recital E Pool One LLC Recital A Pool One LLC Agreement Recital C Property Representation Damage Cap Section 12.05 Rent Rolls Section 8.12 Residence Agreements Section 2.02(c) Sunrise GP Recital B Transferee Default Notice Section 13.02(d) Transferee’s Objection Notice Section 13.02(d) Transferor Default Notice Section 13.02(c) Transferor’s Interest Recital A Transferor’s Non-the-Money Company Option 2.13(aImputation Affidavit Section 3.02(a)(i) In-the-Money Company Warrant 2.14(aTransferor’s Failure of Condition Objection Notice Section 13.02(e) Leased Property 3.14(aTransferor’s Objection Notice Section 13.02(c) Letter Amendment Premable Letter of Transmittal 2.12(aSSLII Preamble Survey Section 3.02(a)(i) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Transferee Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Transferor Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(fTransferee’s Default Notice Section 13.02(d)
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(cDefined Term Section 125 Plan 2.7 (d) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAccounting Firm 3.3 (d) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aBook-Entry Shares 2.9 (c) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 2.3 Claim 2.7 (c) Claim Notice 7.5 (a) Closing 2.4 2.2 Closing Date 2.4 2.2 Closing Working Capital Estimate 2.17(aSpreadsheet 2.8 COBRA 4.21 (f) Company Preamble Company Board Approval 3.5 Recitals Company Certificate 2.10(eD&O Tail Policy 7.14 (a) Company Financial Statements 4.6 (a) Company Indemnified Parties 7.14 (b) Company Plans 4.21 (a) Company Stockholder Approval Recitals DGCL Recitals Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(aArticle 4 Dispute Statement 3.3 (c) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(aDissolved Subsidiaries 4.2 (d) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h2.3 ERISA Affiliates 4.21 (a) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Closing Working Capital Surplus 2.17(b3.3 (a) FDA Requirements 3.19(aExpense Fund 3.6 (e) Final Working Capital 2.17(eGeneral Survival Period 7.6 (a) Firm 11.9 FTC 6.2(aInbound Licenses 4.13 (e) Fundamental Representations 10.2(a)(iiIndependent Company Directors Preamble Insurance Policies 4.23 IP Agreement 4.13 (h) HSR Act 6.2(aKey Employees Preamble Leased Real Property 4.12 Lock-Up Agreement Recitals Defined Term Section Material Contracts 4.16 (a) Indemnified D&Os 6.4(aMerger Recitals Merger Stockholders Preamble Merger Sub Preamble Objection Notice 7.5 (b) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(bOutbound Licenses 4.13 (f) Parent Preamble Parent Closing Balance Sheet 2.17(c) Indemnified Parties 7.2 Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) SEC Documents 6.9 Parties Preamble Paying Agent 2.11(a1.1 (c) Paying Agent Agreement 2.11(aPEO Plan 2.7 (d) Payment Fund 2.11(aPermits 4.18 (b) Post-Closing Statement 3.3 (b) Pre-Closing Statement 3.3 (a) Prospectus Supplement 3.5 (b) Registration Statement 3.5 (b) Released Parties 2.7 (c) Representative Preamble Representative Losses 3.6 (d) Resolution Period 6.1 Preliminary Closing 3.3 (d) Review Period 3.3 (c) SEC 6.9 Share Recipients Preamble Surviving Corporation 2.1 Tax Claim 8.2 (a) Tax Survival Period 7.6 (a) Transactions Recitals Transfer Taxes 8.5 Unaudited Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f4.6 (a)
Appears in 1 contract
Sources: Merger Agreement (Athenex, Inc.)
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(g) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aAudit Claim 9.7(a) Audited Cap 8.4(a) Closing 2.13 Closing Balance Sheet 3.9(b2.7(a) Audited Balance Sheet Date 3.9(b) Audited Financial Statements 3.9(b) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 2.13 Closing Working Capital Estimate 2.17(aStatement 2.7(a) COBRA 3.15(b) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Article 3 Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Preamble Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 5.6 Current Representation 11.16(b) Deductible 8.4(a) D&O Cap 6.4(bIndemnified Parties 5.8(a) Delivered Tax Returns 3.22(aDesignated Person 11.16(b) DGCL Preamble Disclosure Statement 5.8(aDispute Notice 2.7(b) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) 2.12 Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 2.1 Escrow Agreement 2.16 Escrow Fund 2.16 2.15(c) Estimated Closing Cash 2.6 Estimated Closing Indebtedness 2.6 Estimated Closing Net Working Capital Surplus 2.17(b2.6 Estimated Closing Statement 2.6 Estimated Merger Consideration 2.6 Estimated Transaction Expenses 2.6 Expense Fund 2.15(g) FDA Requirements 3.19(aFinancial Statements 3.5(a) Final Working Capital 2.17(eIndemnity Escrow Account 2.15(d) Independent Accounting Firm 11.9 FTC 6.2(a2.7(c) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Latest Balance Sheet 3.9(b3.5(a) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Lease 3.9 Leased Real Property 3.14(a) Letter Amendment Premable 3.9 Letter of Transmittal 2.12(a2.10(b) License Agreement 3.16(a)(xiMaterial Contracts 3.11(a) License Agreements 3.16(a)(xiMaterial Customer 3.22(a) Majority Effective Time Holders 9.1(cMaterial Supplier 3.22(b) Measurement Date 1.1 Merger Recitals Merger Consideration 2.5 MergerSub Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Optionholder Letter 2.11 Paying Agent 2.11(a2.10(a) Paying Agent Agreement 2.11(a2.10(a) Payment Fund 2.11(a2.15(h) PrePayoff Letters 2.14(a)(i) Post-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(aRepresentation 11.16(b) Preliminary Closing Statement 2.17(aPPP Lender 3.26(a) Prior Merger Agreement PPP Loan 3.26(a) Price Adjustment Deficit 2.7(e) Price Adjustment Escrow Account 2.15(c) Price Adjustment Surplus 2.7(e) Privacy Requirements 3.18(d) Purchaser Preamble Related Agreements 3.5(aQualified Plan 3.15(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iiiSales Tax Indemnity Escrow Account 2.15(e) Specified Representations 10.2(a)(iiiSecurityholder Payment Schedule 2.8 Surviving Company 2.1 Stockholder Written Consent Recitals Tax Indemnity Escrow Account 2.15(f) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Transfer Taxes 9.6 Warranty Obligations 3.27
Appears in 1 contract
Additional Defined Terms. The In addition to the terms defined in Section 1.01, the following terms shall have are defined in the meanings set forth on the pages corresponding Section of this Agreement indicated below: 280G Approval 6.3(cAgreement. Term Section Accounting Firm 3.03 (b) 280G Payments 6.3(cAccounts Receivable 5.05 (f) Acquisition Proposal 5.11 Acquisition Sub Preamble Agreed Claims 10.4(gAdjustment Escrow Account 2.06 (a) Adjustment Escrow Amount 2.05 (a)(i) Adjustment Escrow Shortfall 2.06 (b)(ii) Agreement Preamble Agreement Date Asset Purchase 2.02 Asset Seller Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b5.05 (a) Audited Financial Statements 3.9(b5.05 (a) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iiiAuthorized Action 12.15 (c) ▇▇▇▇▇ Law 3.12(b4.06 Business Recitals Business Intellectual Property 5.12 (a) Stockholder Approval 3.8 Stockholder Meeting 5.8(bBuyer Preamble Buyer Disclosure Schedules Article 6 Buyer Indemnified Persons 11.02 Buyer Plans 8.02 (b) Straddle Buyer Return 8.04 (b) Claims 8.05 (c) Closing 3.01 Closing Date 3.01 Closing Date Balance Sheet 3.03 (a) Company(ies) Recitals Company Benefit Plans 5.17 (a) Company Data 5.12 (h) Company Disclosure Schedules Article 5 Company Employees 5.16 (a) Company Indemnified Parties 8.03 (a) Company Intellectual Property 5.12 (a) Company Subsidiaries 5.04 (a) Company Subsidiary Interests 5.04 (a) Company Systems 5.12 (f) Continuing Company Employee 8.02 (a) Data Policies 5.12 (i) Defense Notice 11.05 (a) Disclosing Party 8.05 (d) D&O Tail Policy 8.03 (c) EAR 5.24 (b) Equity Interests Recitals Equity Purchase 2.01 Equity Sellers Preamble Escrow Agent 2.05 (a)(i) Escrow Agreement 2.05 (a)(i) Escrow Amount 2.05 (a)(i) Estimated Closing Purchase Price 2.04 Estimated Closing Statement 2.04 Excluded Persons 8.06 (c) Existing Policies 11.06 (f) Final Closing Cash 3.03 (b) Final Closing Date Statement 3.03 (a) Final Closing Indebtedness 3.03 (b) Final Closing Working Capital 3.03 (b) Final Purchase Price 3.03 (b) Final Seller Transaction Expenses 3.03 (b) Financial Statements 5.05 (a) Former Holder 12.15 (b) ▇▇▇▇▇▇▇ ▇▇▇▇ 12.14 (a) Indemnity Escrow Account 2.06 (a) Indemnity Escrow Amount 2.05 (a)(i) Indemnified Party 11.04 (a) Indemnifying Party 11.04 (a) Individual Breach 11.02 Insurance Policies 5.19 Interim Balance Sheet Date 5.05 (a) Interim Financial Statements 5.05 (a) IRS 5.17 (d) Lease 5.10 (a) Leased Real Property 5.10 (a) Material Contracts 5.13 (a) Material Customers 5.22 (a) Material IP Agreements 5.12 (a) Material Suppliers 5.22 (b) Multiemployer Plan 5.17 (a) Non-U.S. Benefit Plan 5.17 (a) Notice of Disagreement 3.03 (b) Party(ies) Preamble Payoff Letters 3.02 (a)(vii) Post-Closing Seller Employee Bonus Payments 8.04 (h) Privileged Communications 12.14 (a) Prop 65 5.23 (f) Purchase Price 2.03 (a) Receiving Party 8.05 (d) Registered Intellectual Property 5.12 (a) Releasee 8.05 (c) Releasor 8.05 (c) Representatives 6.09 Restricted Period 1.1 Subsidiary Securities 3.2(b8.06 (c) Survival Date 10.3(aSales Tax Proceedings 8.04 (j)(i) Security Incident 5.12 (k) Seller Disclosure Schedules Article 4 Seller Group 12.14 (a) Seller Indemnified Persons 11.03 Seller Return 8.04 (a) Seller Transaction Expenses Certificate 3.02 (a)(xvii) Sellers Preamble Sellers’ Representative 12.15 (a) Senior Employee Agreements Recitals State Sales Tax Liabilities 8.04 (j) State Sales Tax Liability Proceedings 8.04 (j)(i) Successor Holder 12.15 (b) Tax Escrow Account 2.06 (a) Tax Escrow Amount 2.05 (a)(i) Territory 8.06 (c) Third Party Person 11.05 (a) Third Person Claim 10.4(b11.05 (a) Working Capital Deficit 2.17(fTransaction Expenses 12.01 (a) Working Capital Objection Period 2.17(eVCG Assignment and Assumption Agreement 3.02 (a)(ii) Working Capital Objection Statement 2.17(eVDA 8.04 (j) Working Capital Surplus 2.17(f)VDA Proceeding 8.04 (j) Vionic Entities Recitals Vionic Group Recitals Vionic International Recitals Warrant Cancellation Agreement Recitals Weil Recitals
Appears in 1 contract
Additional Defined Terms. The As used in this Deed, the following terms shall have the meanings set forth on defined in the pages of this Agreement Preamble, Recitals or clause as indicated below: 280G Approval 6.3(cAdjustment Time Clause 2.4.1(a) 280G Payments 6.3(cBabitzova Preamble Babitzova Shares SCHEDULE 1 Buyer Preamble Buyer Documents Recital F Collective License Agreements Clause 3.16.1(f) Acquisition Proposal 5.11 Acquisition Sub Company Recital A Completion Clause 7 Completion Date Clause 7.1 Completion Date Current Assets Clause 2.4.1 Completion Date Liabilities Clause 2.4.1 Completion Date Net Worth Clause 2.4.1 Confidential Information Clause 9.1 Deed Preamble Agreed Claims 10.4(gDisclosing Party Clause 9.1 Emmis Preamble Emmis Shares SCHEDULE 1 Expres Media Recital C Expres Net Recital C Guarantee Clause 8.2 Guarantor Preamble Initial Purchase Price Clause 2.2.3 Information Technology Clause 3.14.6 Licensed IP Right(s) Agreement Clause 3.14.4 Objection Report Clause 2.4.3 Owned IP Right(s) Clause 3.14.1 Owned Real Property Clause 3.7.1 Party or Parties Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(a) Audited Balance Sheet 3.9(b) Audited Balance Sheet Date 3.9(b) Audited Pension Commitments Clause 3.12.4 Preliminary Purchase Price Report Clause 2.3.1 Preliminary Purchase Price Clause 2.3.1 Pro-Forma Consolidated Financial Statements 3.9(b) California Stockholder Clause 3.8.3 Receiving Party Clause 9.1 Regulatory Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Closing 2.4 Closing Date 2.4 Closing Working Capital Estimate 2.17(a) Company Recital D Relevant Matter Clause 4.6 Seller or Sellers Preamble Company Board Approval 3.5 Company Certificate 2.10(e) Company Disclosure Schedule 3.0 Company Disclosure Schedules 3.0 Company Option 2.13(a) Company Preferred Stock 2.10(b) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Seller Documents 2.12(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 D&O Cap 6.4(b) Delivered Recital D Seller Objection Report Clause 2.4.3 Shares Recital A Station Recital B Subsidiaries Recital C Tax Returns 3.22(a) DGCL Preamble Disclosure Statement 5.8(a) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h) Employee Plan 3.15(h) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(f) Escrow Agent 2.16 Escrow Agreement 2.16 Escrow Fund 2.16 Estimated Working Capital Surplus 2.17(b) FDA Requirements 3.19(a) Final Working Capital 2.17(e) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) HSR Act 6.2(a) Indemnified D&Os 6.4(a) Indemnified Parties 10.1(a) Interim Balance Sheet 3.9(b) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(a) Leased Property 3.14(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xi) Majority Effective Time Holders 9.1(c) Measurement Date 1.1 Merger Preamble Option Cancellation Agreement 2.13(c) Organizational Documents 3.3 Out-of-the-Money Company Option 2.13(b) Out-of-the-Money Company Warrant 2.14(b) Outside Date 8.1(b) Parent Preamble Parent Closing Balance Sheet 2.17(c) Parent Representatives 5.9 Parent Working Capital Determination 2.17(c) Parent Working Capital Statement 2.17(c) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period Clause 6.3 Tax Indemnification Claim Clause 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Specified Representations 10.2(a)(iii) ▇▇▇▇▇ Law 3.12(b) Stockholder Approval 3.8 Stockholder Meeting 5.8(b) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(a) Third Party Claim 10.4(b) Working Capital Deficit 2.17(f) Working Capital Objection Period 2.17(e) Working Capital Objection Statement 2.17(e) Working Capital Surplus 2.17(f)Tax Indemnification Notice Clause 6.2 Tax Reduction Clause 6.3
Appears in 1 contract
Additional Defined Terms. The For purposes of this Agreement, the following terms shall have the meanings set forth on specified in the pages indicated Section of this Agreement indicated belowAgreement: 280G Approval 6.3(c) 280G Payments 6.3(c) Acquisition Proposal 5.11 Acquisition Sub Preamble Defined Term Section Agreed Claims 10.4(gPortion 10.3(b) Agreement Preamble Agreement Date Preamble Allocation Certificate 6.8 Antitrust Filings 6.2(aApplicable D&O Claim 10.5(e) Audited Applicable Escrow Final Indian Tax Reimbursement Shortfall 10.3(g)(iii) Applicable Escrow/Setoff Final Indian Tax Reimbursement Shortfall 10.3(g)(iii) Applicable Excess 10.3(g)(ii) Asserted Losses 10.3(a) Assumed Option 6.11 Assumed Option Exercise Price 6.11 Assumed Option Holder 6.11(a)(i) Assumed Option Spread Value Per Share 6.11(a)(ii) Balance Sheet 3.9(b4.5(a)(i) Audited Balance Sheet Date 3.9(bBlock Trade 3.9(c) Audited Financial Statements 3.9(bCertificate 3.3(a)(i) California Stockholder Approval 3.8 Certificate of Merger 2.4 Claims 10.4 CLIA 1.1 Commissioner 4.3 Change in Recommendation 6.9(b) Charter Amendment 6.19 Closing 2.4 2.2 Closing Date 2.4 2.2 Closing Date Net Working Capital Estimate 2.17(aStatement 3.6(c) Closing Disbursement 2.2(c)(ii) COBRA 4.16(c) Company Preamble Company Board Approval 3.5 Company Certificate 2.10(eRecommendation 6.9(a) Company Disclosure Schedule 3.0 Article 4 Company Disclosure Schedules 3.0 Indemnified Parties 10.2 Company Option 2.13(aIntellectual Property 4.13(a) Company Preferred Stock 2.10(bMateriality Qualified Provisions 10.1 Company Representatives 6.5(a) Company Representative 5.11 Company Software 3.18(l) Company Third Party Consents 6.3(b) Company Warrant 2.14(a) Company Warrant Documents 2.12(aSpecified Representations 10.5(a) Confidentiality Agreement 5.9 Corporate Stockholder Approval 3.8 6.6(a) Contingent Assumed Option 6.11(a)(iii) Contingent Payment Amounts 6.11(b) Contractors 4.17(b) Controlling Party 10.3(e) D&O Cap 6.4(bIndemnified Parties 6.17(a) Delivered Tax Returns 3.22(aDe Minimis Amount 10.5(c) Deposit 9.4(d) DGCL Preamble Disclosure Statement 5.8(a2.1 Disputed Line Items 3.8(b) Dissenting Shares 2.15 Dissenting Stockholders 2.15 DOJ 6.2(a3.5 DOL 4.16(b)
(a) Earn-Out Shares 3.1(c) Earn-Out Statement 3.7(a) Effective Time 2.4 Employee Pension Benefit Plan 3.15(h2.2(a) Employee Plan 3.15(hEmployment Agreement Preamble End Date 8.1(b) Employee Welfare Benefit Plan 3.15(h) Environmental Approvals 3.21(e) Environmental Reports 3.21(fEscrow Account 2.2(c)(i) Escrow Agent 2.16 2.2(c)(i) Escrow Agreement 2.16 2.2(c)(i) Escrow Fund 2.16 Final Indian Tax Reimbursement 10.3(g)(iii) Escrow Shares 2.2(c)(i) Estimated Amount 10.3(g)(ii)
(a) Estimated Net Working Capital Surplus 2.17(bStatement 3.6(a) FDA Requirements 3.19(aExchange Agent 2.2(c)(ii) Exchange Agent Agreement 2.2(c)(ii) Expense Reimbursement 8.3(a)(ii) Fairness Approval 6.8(b) Fairness Hearing 6.8(b) Final Closing Net Working Capital 3.6(d) Final Indian Tax Amount 10.3(g)(ii) Final Net Working Capital Shortfall Reimbursement Amount 3.6(d)(ii) Final Working Capital 2.17(ePayment Amount 3.6(d)(i) Financial Statements 4.5(a) Firm 11.9 FTC 6.2(a) Fundamental Representations 10.2(a)(ii) 11.16 Holder Representative Preamble Holder Representative Agreement 11.5 HSR Act 6.2(a4.3 Indemnification Demand 10.3(a) Indemnified D&Os 6.4(aParty 10.3(a) Indemnified Parties 10.1(aIndemnifying Party 10.3(a) Independent Accounting Firm 3.8(c) Indian Proceeding 10.3(g)(i) Indian Proceeding Amount 10.3(g)(i) Indian Proceeding Notice 10.3(g)(i) Information Statement 6.8(a) Interim Balance Sheet 3.9(b4.5(a)(ii) Interim Balance Sheet Date 3.9(b) Interim Financial Statements 3.9(b) In-the-Money Company Option 2.13(a) In-the-Money Company Warrant 2.14(aIntervening Event 6.9(c)(ii) Leased Real Property 3.14(a4.12(a) Letter Amendment Premable Letter of Transmittal 2.12(a) License Agreement 3.16(a)(xi) License Agreements 3.16(a)(xiLock-Up Restriction 3.9(c) Majority Effective Time Holders 9.1(c11.1(b) Measurement Date 1.1 Malicious Code 4.13(j) Merger 2.1 Merger Sub Preamble Multiemployer Plan 4.16(c) New Health Plans 6.18(b) New Plans 6.18(b) Non-Contingent Assumed Option Cancellation Agreement 2.13(c6.11(a)(iv) Organizational Documents 3.3 OutNon-of-the-Money Company Option 2.13(bReleasable Options 6.11(d) Out-of-the-Money Company Warrant 2.14(bNotice of Disagreement 3.8(b) Outside Date 8.1(bOld Health Plans 6.18(b) Parent Original Vesting Requirements 6.11 Parties Preamble Parent Closing Balance Sheet 2.17(cPension Plan 4.16(b) Parent Representatives 5.9 Parent Working Capital Determination 2.17(cPermit Application 4.3 Presented Values 3.8(a) Parent Working Capital Statement 2.17(cPrice Ratio 6.11(a)(v) Paying Agent 2.11(a) Paying Agent Agreement 2.11(a) Payment Fund 2.11(a) Pre-Closing Period 6.1 Preliminary Closing Balance Sheet 2.17(a) Preliminary Closing Statement 2.17(a) Prior Merger Agreement Purchaser Preamble Related Agreements 3.5(a) Seller Group 11.19 Series D Stock 1.1 Special Representations 10.2(a)(iii) Purchaser Disclosure Schedule Article 5 Purchaser Indemnified Parties 10.1 Purchaser Materiality Qualified Provisions 10.2 Purchaser Specified Representations 10.2(a)(iii10.5(b) Qualified Plan 4.16(b) Qualifying Royalty Revenue Period 3.7(a) Qualifying Royalty Revenues 3.7(a) Registration Statement 4.3 Reimbursed Indian Taxes 10.3(g)(iv) Releases 2.2(b)(i)(B) Representative Losses 11.1(d) Response 10.3(b) Retention Plan Participant List 6.22 ▇▇▇▇▇▇▇▇-▇▇▇▇▇ Law 3.12(bAct 5.6(a) Scheduled Release Date(s) 6.11(c) SEC Reports 5.6(a) Seller Group 11.16 Setoff Amount 10.3(g)(ii) Share Ratio 6.11(a)(vi) Stockholder Approval 3.8 Requirements 6.13 Stockholder Meeting 5.8(bVote 4.2 Subsequent Monthly Financial Statements 6.15 Surviving Corporation 2.1 Tax Contest 9.4(a) Straddle Period 1.1 Subsidiary Securities 3.2(b) Survival Date 10.3(aTermination Fee 8.3(b) Third Party Claim 10.4(bClaims 10.3(e) Working Capital Deficit 2.17(fThird Party Intellectual Property 4.13(c) Working Capital Objection Period 2.17(eThreshold 10.5(c) Working Capital Objection Statement 2.17(eTitle IV Plan 4.16(c) Working Capital Surplus 2.17(fTransfer 3.9(c) Transfer Taxes 9.3 Transmittal Documentation 3.3(a)(i) Transmittal Letter 3.3(a)(i) Trillium Contracts 3.7(a) Unsatisfied Amount 10.3(g)(ii) Voting Agreements Preamble Withholding Agents 3.10(a)
Appears in 1 contract
Sources: Merger Agreement (Radisys Corp)